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Gene expression regulation is a set of critical biological processes that give rise to the diversity of 
cell types across tissues and development stages. Noncoding regions of the genome (intergenic + 
intronic, >98% genome) play an important role in these processes, with noncoding genetic variation 
quantitatively affecting transcriptional activity, splicing of pre-mRNA, and localization, stability, and 
translational control of mRNA transcripts. Previous genetic studies of human disease have implicated 
numerous common noncoding loci with small but significant effect in common conditions. Recently, 
we and others have reported evidence supporting a role of rare noncoding variants with larger effect 
in early onset conditions such as birth defects and neurodevelopmental disorders. These early onset 
conditions are quite common in aggregate, affecting over 3% of young children. Better understanding 
of the functional impact of rare regulatory noncoding variants will enable novel genetic discovery, 
give insights of disease mechanisms, and ultimately improve diagnosis, treatment, and clinical care. 
In this thesis dissertation, I describe three related projects. First, we used a combinatorial multi-
testing framework to find excess burden of noncoding de novo mutations in congenital heart disease 
(impacting both transcriptional and post-transcriptional regulatory stages). This finding was central 
to the rest of my work, motivating the development of new computational approaches to predict 
genetic effect of noncoding variants through the lens of post-transcriptional regulation. Second, we 
used convolutional neural networks to model and understand sequence specific RBP binding 
processes. Finally, we designed a graphical neural network model capable of integrating cause and 
consequence to predict genetic effect of rare noncoding variants. In summary, we developed new 
machine learning methods to analyze multimodal human genome sequencing data, uncover deeper 
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0.1 The regulation of gene expression and functional impact of noncoding genetic 
variation  
 
The human genome is composed of double-stranded deoxyribonucleic acids (DNA), which 
encode genetic information with sequentially ordered nucleotide pairs (cytosine [C] with guanine 
[G]; adenine [A] with thymine [T]) kept in a double helix structure. DNA is packaged into 
chromosomes, composed of genic regions with intergenic space in between (Figure 0.1). Each 
gene is usually made up of exons (expressed regions) and introns and is flanked on both sides by 
5’ and 3’ untranslated regions (UTRs) (Figure 0.1). Transcription of DNA to messenger RNA is 
regulated by transcription factors (TFs), which bind to promoters and enhancers to control 
recruitment of RNA polymerase. During transcription, introns are spliced out and the remaining 
genomic sections are connected together (from 5’ to 3’ end) into single-stranded ribonucleic 
acids (RNA). Later, in the post-transcriptional modification and translation steps, messenger 
RNA (mRNA) is prepared, UTRs removed, and coding exonic sequence used to direct building 
protein product out of amino acids. In general, proteins are the functional unit that then fulfill 
tasks in the cells of the organism, and coding mutations have been associated with human genetic 
disease since 1956, when Ingram, Hunt and Stretton showed beta-globin amino acid substitution 
is linked to sickle cell anemia [1-4]. Since then, there has been much research into how coding 
mutations can disrupt proper protein 3D structure and function, as well as intensive method 
development for prediction of coding variant effects. 
On the other hand, noncoding regions, including introns and intergenic genomic regions, 
represent the >98% parts of the genome that are never turned into protein product. Although 
previously thought to be inconsequential, it is now understood that this DNA includes critical 
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elements that affect the expression of each gene’s protein product; indeed, typical regulatory 
sites for genes are near the transcription start site and 3’UTR regions, as well as within introns 
for splicing. Overall, gene expression regulation gives rise to the diversity of cell types in human 
and other organisms. Since dosage of genes needs to be tightly regulated across both tissues 
(spatially) and development (temporally), noncoding genetics is thus very important, and deep 
analysis of noncoding regulatory variant impacts is critical to understanding overall disease 
genetics. 
 
Figure 0.1. Illustration of DNA packaging into chromosomes, and composition of genic and 
intergenic regions.  
Noncoding regions are intronic + intergenic. This illustration has been adapted from Figure 1 of 
Huang, W., et al., 2014 [5] and Figures 10.17 and 10.17 and 10.25 of Rice University’s OpenStax 
Microbiology book [6, 7]. 
 
Normal regulation of gene expression is controlled at both 1. The transcriptional stage, 
mediated by transcription factors (TFs) and chromatin modifications and 2. The post-
transcriptional stage, including RNA processing, transport, and translation control, mediated by 
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RNA binding proteins (RBPs). Regulatory noncoding variants have been directly implicated in 
disease more recently than coding mutations; an important early paper was Reamon-Buettner 
2007, which looked at CHD patient blood and identified seven impactful noncoding mutations in 
3’UTR of GATA4 that seemed to knockout GATA4 expression via changing RNA secondary 
structure [8]. Many genes coding for specific RBPs have also been implicated in disease using 
Whole Exome Sequencing (WES), such as RBFOX2 (via mostly splicing control) in CHD 
(Homsy 2015)[9], and FMRP/FMR1 (via mostly localization and transport control) in autism (De 
Rubeis 2011, 2014) [10, 11]. In this dissertation, I will focus on the still relatively understudied 
post-transcriptional regulation, both in our initial analysis of congenital heart disease variants 
and in our later method development for modeling RBP binding and disruption effects. 
 
 
0.2 Introduction to developmental disorders 
 
Developmental disorders are altogether some of the most common and lethal human birth 
defects, yet much about their genetics and biology is still unknown. Congenital diaphragmatic 
hernia (CDH) appears in 1 in 3000 births, representing 8% of all birth defects; isolated cases 
have 20%-40% mortality, which can rise as high as 50% when combined with other conditions 
(complex/syndromic cases) [12, 13]. Even in milder cases, developmental delays are common 
and many CDH patients have additional congenital anomalies or neurodevelopmental disorders. 
Congenital heart disease (CHD) is an even more widespread condition, occurring in a massive 
1% of live births [14]. Like with CDH, it can occur both in isolated and syndromic contexts and, 
despite marked improvements in survival due to modern surgical and medical management, it is 
still usually highly debilitating and often lethal. Indeed, complex CHD cases that also exhibit 
CDH have a mortality rate over 25% [12-14]. Furthermore, the decrease in infant mortality from 
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CHD has increased the prevalence of the disorder in older individuals, including adults, and 
exposed co-morbidities that impair quality of life as well as life expectancy. In aggregate, early 
onset conditions including these birth defects and neurodevelopmental disorders are quite 
common, affecting over 3% of young children [15], and a deeper knowledge of genetics is 
urgently needed to enable improved diagnosis, treatment, and clinical care. 
 
0.3 Contribution of noncoding regulatory variants to disease 
 
Previous studies (Homsy 2015, Jin 2017) found significant contribution of coding de novo 
variants to congenital heart disease, accounting for 10-20% of syndromic cases as well as a non-
zero but much smaller fraction (2%) of isolated cases [9, 16]; CDH follows a similar pattern, 
with ~30% coding de novo contribution [17]. Given this understanding, the natural research 
direction to try to understand the 80% of syndromic cases and more than 90% of isolated cases 
that do not have damaging de novo variants in coding regions pursue is to investigate the 98% of 
the genome that is noncoding. We are primarily interested in finding genetic causes with large 
effect, for clearer application to genomic medicine. Given the severity and early onset of CHD 
and other developmental disorders, such variants are likely under strong negative selection. 
Therefore, we focus on rare variants, in particular de novo noncoding variants in families with 
unaffected parents. 
As we introduced in Section 0.1, previous genetic studies of human disease have established 
a role of rare noncoding variants in disease. In addition to the aforementioned Homsy 2015 and 
De Rubeis 2014, which used exome sequencing to implicate RBP genes in CHD and autism, 
respectively, there have since been several studies directly linking rare regulatory noncoding 
variants to early onset conditions and other diseases. Notable studies in the last few years include 
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the DDD (Deciphering Developmental Disorders) consortium’s analysis of 7,930 
neurodevelopmental disorders trios [18], and an ICGC (International Cancer Genome 
Consortium) study of 2,583 cancer trios [19]; relevant pathway enrichment was observed with 
coding and noncoding variants, in both research efforts. My work seeks to clarify this substantial 
and previously underestimated contribution of noncoding region variants (particularly those 
disrupting gene regulatory processes) to disease. 
The significance of this project to human disease and medicine can thus be summarized by 
two points: a) Insight into the genetic architecture of developmental disorders, including 
implication of new noncoding rare and de novo mutations and discovery of new candidate genes, 
and b) Genetic diagnosis, making it possible to explain a certain fraction of patients with early 
onset diseases, and to make useful medical predictions for later onset disorders relying on the 
same specific genetic machinery. Knowledge of the functional impact of regulatory noncoding 
variants will enable novel genetic discovery, deeper understanding of disease mechanisms, and 
ultimately improved diagnosis, treatment, and clinical care. 
 
0.4 RNA binding proteins and eCLIP data 
 
There are ~1500 (600 structurally distinct) RBPs in humans [20], which control several 
interlocking post-transcriptional regulatory processes: splicing of pre-mRNA, and localization, 
degradation, and translational control of mRNA transcripts.  RBPs have binding preference to a 
diverse range of regions on transcripts: 3’UTR, 5’UTR, splice sites, distal and proximal intron, 
and sometimes exons, depending on their specific functions [21]. In the past few years, large 
efforts such as the ENCODE (Encyclopedia of DNA Elements) project [22] have performed 
eCLIP (enhanced crosslinking and immunoprecipitation) experiments to capture in vivo binding 
6 
 
of these RNA binding proteins [23]. However, our current understanding of the impact of genetic 
variation on RBP-RNA interaction is limited due to the complex nature of RBP binding: 
although RBP binding is foremost driven by biochemical recognition of specific sequence 
motifs, many other factors such as RNA secondary structure and tissue-specific epigenomic 
patterns also contribute. Indeed, most motifs still remain unknown [24] due to limited in vivo 
binding data (from a very small selection of cell types), and a complicated relationship between 
raw sequence and true biological binding of RBPs: mere presence of a motif alone does not 
guarantee binding at a genomic site in a particular tissue. In future, more data from primary cells 
and many cell types would be invaluable for developing a more comprehensive understanding of 
tissue-specific RBP binding. 
 
0.5 Organization of this dissertation 
 
The remainder of this dissertation is organized into three chapters: 
 
In Chapter 1, I discuss our analysis of Whole Genome Sequencing for a large congenital 
heart disease (CHD) study, and the initial evidence of the contribution of noncoding de novo 
variants to genetic risk of CHD mediated by RBPs. This study motivated all of the remaining 
questions in this dissertation thesis. 
 
In Chapter 2, I present POLARIS, a new method based on convolutional neural networks 
that predicts RBP binding to transcripts. I will discuss our exploration of its feature encoding 
and applicability to post-transcriptional regulation studies. 
Finally, in Chapter 3, I discuss our work in designing a graphical neural network model for 
predicting functional impact of noncoding variants mediated by RBPs. The graphical model 
integrates evidence of RBP binding changes and selection effect in human populations. 
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Chapter 1: The contribution of noncoding de novo variants to 
genetic risk of CHD mediated by RNA binding proteins 
 
A genetic etiology can be identified for one third of patients with congenital heart disease 
(CHD), including 8% attributable to coding de novo variants (DNVs). To assess the contribution 
of noncoding DNVs, we worked together with other researchers in the NHLBI-funded Pediatric 
Cardiac Genomics Consortium (PCGC) to analyze whole genome sequence data from 749 CHD 
probands and their parents and 1,611 control trios (unaffected siblings and their parents from the 
Simons Simplex Collection study on autism). Three parallel approaches were developed to study 
the impact of noncoding variants on both transcriptional and post-transcriptional regulation. Two 
of the strategies focused on transcriptional regulation by annotations of cardiac gene regulatory 
elements via: 1. Use of a qualitative neural network model tuned specifically for developing 
heart tissue to predict functional impacts with variant-level resolution, and 2. Analysis of 
multiple DNVs in genes with human fetal heart enhancers overlapping open chromatin during 
cardiomyocyte differentiation. Both of these approaches found significant burden of noncoding 
variants disrupting transcriptional regulatory processes (p=8.7x10-4, p=1x10
-5, respectively), and 
significant overlap between their results was observed (OR=2.5, 95% C.I. 1.1-5.0, p=5.4x10-3). 
My contribution to the project concentrated on the third strategy, which focused on disruption of 
RBP-mediated post-transcriptional regulation by noncoding de novo variants. We observed a 
significant burden of noncoding DNVs located in plausible transcribed regions through which 
RBPs regulate post-transcriptional process during heart development (OR=1.13, 95% C.I. 1.1-
1.2, p=8.8x10-5). Altogether, our findings demonstrate an enrichment of noncoding DNVs that 
may disrupt transcriptional and post-transcriptional heart regulatory elements in a fraction of 





Congenital heart disease (CHD) is the most common type of birth defect, occurring in 1% of 
live births [14]. Although modern surgical treatments and medical management have greatly 
reduced infant mortality rate [14], the resultant rise in survival has increased prevalence of CHD 
in older individuals, exposing co-morbidities that impair quality of life and life expectancy even 
into adulthood. As efforts to improve these outcomes might benefit from elucidation of CHD 
etiologies and a better understanding of the genetic mechanisms, the NHLBI-funded Pediatric 
Cardiac Genomics Consortium (PCGC) [25] recruited >13,000 patients and utilized Whole 
Exome Sequencing (WES) and chromosome microarrays to study the genetic architecture of 
CHD. PCGC analyses identified damaging rare transmitted and de novo variants (DNVs) in 8% 
of sporadic cases of CHD (including 28% of syndromic and 3% of isolated CHD) [9, 25, 26], 
with many DNVs identified in CHD patients altering proteins with regulatory functions in 
chromatin modification, transcription control, and RNA processing [9].  
Based on these findings, we hypothesized that additional causes of CHD may reside in 
noncoding elements that regulate gene expression during cardiac development, and which could 
elucidate some of the >70% of cases currently unexplained by coding variants. To explore this 
idea, we performed Whole Genome Sequencing (WGS) to identify single nucleotide variants 
(SNVs) and small insertions/deletions (indels) in 763 CHD trios comprised of affected probands 
and unaffected parents and in 1611 child-parent trios without CHD [27]. We compared 
noncoding DNVs using three parallel approaches in the cohort. Two strategies focused on 
annotations of cardiac gene regulatory elements via: 1. Application of a neural network model 
(HeartENN) to predict heart-specific functional impact of variants within these regions and 2. 
Analysis of multiple DNVs in genes with human fetal heart enhancers overlapping open 
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chromatin during cardiomyocyte differentiation. My contribution focused on a third strategy, 
with the intuition that we can use a combination of RNA binding protein (RBP) binding sites and 
tissue-specific genomic data (such as relevant epigenomic marks) as indications of plausibility of 
disrupting post-transcriptional regulation. We interrogated variants that potentially disrupt RBP 
binding, and found evidence for significant enrichment of these noncoding DNVs in cases. 
Taken together, these results demonstrated a contribution of noncoding DNVs to CHD through 




1.2.1 Trio cohort characteristics and sequencing 
 
We performed WGS (average depth ~30X) on 763 CHD probands (311 with extra-cardiac 
anomalies; 452 with isolated heart malformations) and unaffected parents enrolled by the 
Pediatric Cardiac Genomics Consortium (PCGC) [25]. The trios are described in Supplemental 
Table 1a (with phenotype summary in Supplemental Table 1b) in our paper Richter, et al., 2020 
[28], available online. To increase the chance of finding causal noncoding variants, cases for 
WGS were selected only if prior exome sequencing studies [16] failed to identify rare damaging 
missense or loss-of-function coding variants in known or candidate CHD genes (Supplemental 
Table 5 in Richter, et al., 2020 [28]). We also studied de novo variants (DNVs) in 1611 trios 
from the Simons Simplex Collection (SSC)[27] autism control group: these are unaffected 
siblings and parents of autism patients, and were selected to have had no past medical history of 
autism or CHD. To ensure accurate variant detection, DNVs were identified using Genome 
Analysis Toolkit (GATK) software [29] and then further evaluated with two additional 
computational pipelines: a) local realignment and assessment by FreeBayes [30] and b) 
classification by a neural network trained on Integrated Genomics Viewer (IGV) plots [31]; 
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ambiguous variants were resolved with manual curation. The consensus frozen sets of variants 
for CHD cases and SSC controls are listed in Supplemental Tables 2 and 3, respectively, in 
Richter, et al., 2020 [28]. We confirmed the robustness of our calling procedure with PCR-based 
Sanger sequencing, validating 98% of 266 de novo single nucleotide variants (SNVs) and 94% of 
83 de novo indels in cases. Furthermore, in controls (unaffected SSC siblings), 94% of de novo 
SNVs were also reported in at least one published analysis of the same individuals [31, 32]. We 
identified a mean of 71 de novo SNVs and five de novo indels per CHD proband (58,090 DNVs), 
and 68 de novo SNVs and five de novo indels per control subject (117,344 DNVs); these 
frequencies are similar to WGS data obtained on similar platforms and coverage [33]. 
 
1.2.2 Whole Genome Sequencing quality control: quantifying de novos / sample 
 
De novo variants / sample and paternal age (at conception) are known to have a positive 
correlation [34]. We leverage this fact to perform quality control prior to statistical analysis. The 
idea is to regress the number of DNVs over paternal age, and then compare regression 
parameters between different WGS batches: CHD (cases) and SSC (controls) in our case, and 
ensure that they have similar slope and intercept, as well as comparable age distributions. Slope 
represents the relationship between de novo count and paternal age, which should be independent 
of WGS batch, while significantly different intercept would indicate technical artifacts. 
Comparison of CHD and SSC yielded no batch effects, and very similar overall noncoding 




Figure 1.1. WGS de novos quality control plot 
No batch effects were observed between cases (CHD) and controls (unaffected siblings of 
Simons Simplex Complex autism cases, collected by SFARI consortium and selected to also 
not have any developmental disorders, including CHD). Furthermore, relationship (slope) 
between de novo count and paternal age was stable across batches, with consistent intercept. 
 
The exact correlation of the number of DNVs per subject with both paternal and maternal age 
was estimated precisely with multiple variable linear regression. As expected, the former was 
stronger (βCHD=1.4, pCHD=5x10
-54, βcontrol=1.4, pcontrol=6x10
-86) than the latter (βCHD=0.5, 
pCHD=2x10
-5, βcontrol=0.4, pcontrol=3x10
-8). Most of the association was driven by SNVs, but there 
was also an association between de novo indels and paternal (βCHD=0.07, pCHD=2x10
-4, 
βcontrol=0.05, pcontrol=3x10
-4) but not maternal age (βCHD=0.01, pCHD=0.6, βcontrol=0.03, 
pcontrol=0.1). Without adjusting for parental age, cases had more DNVs per affected proband than 




difference, subsequent comparisons were made with respect to the total number of DNVs 
observed in CHD probands and controls.  
 
1.2.3 Implication of noncoding variants in transcriptional regulation 
 
Transcriptional regulatory disruption was investigated with two separate approaches: 1. 
application of a neural network (HeartENN) to predict cardiac epigenomic transcriptional impact 
of noncoding DNVs, and 2. independent analyses of human fetal cardiac enhancers, prioritized 
with overlap of open chromatin during differentiation of human induced pluripotency cells into 
cardiomyocytes (iPSC-CMs). Both of these approaches found significant burden of noncoding 
variants disrupting transcriptional regulatory processes (p=8.7x10-4, p=1x10
-5, respectively), and 
significant overlap between their results was observed (OR=2.5, 95% C.I. 1.1-5.0, p=5.4x10-3); 
details of these methods are described in Richter, et al., 2020 [28]. 
 
1.2.4 Multi-test framework for investigating burden in noncoding variant classes 
 
In addition to exploring disruption of transcriptional regulation, we were also interested in 
possible enrichment of de novo noncoding variants affecting post-transcriptional regulatory 
processes. As mentioned in the Introduction section, post-transcriptional regulation is largely 
mediated by complexes of RNA-binding proteins (RBPs), and includes pre-mRNA splicing, 
transport, localization, degradation, and translational control. We obtained eCLIP (enhanced 
crosslinking and immunoprecipitation) RBP binding data from ENCODE [22], from experiments 
originally done by Gene Yeo’s group at UCSD [23]. eCLIP data is stored as rows of peaks that 
specify chromosome, start, and end position of each detected binding site, together with an 
associated p-value. Of course, because they are derived from imperfect physical experiments, 
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there is some noise in the data. Chaolin Zhang’s group developed a new method to refine the 
binding signal from eCLIP datasets (“CLIP Tool Kit” [35]) and it is this latest processed data 
that we use in our analyses. In total, we acquired binding data for 112 unique RBPs from the 
adrenal gland, HepG2, and K562 cell lines, for a total of 160 separate RBP eCLIP peak files.  
Because there are no available eCLIP data from cardiac tissues, we selected eCLIP binding 
sites that have a plausible role in heart development by considering only those binding peaks that 
overlap with the active transcription mark H3K36me3 in human fetal heart (a feature also used in 
HeartENN) and human embryonic stem cells (not used in HeartENN or prioritized human fetal 
heart enhancers). Using this narrower definition of RBP binding sites, we then performed an 
unbiased noncoding burden analysis for cases vs. controls, for all 162 combinations of the 
following annotation features: specific H3K36me3 histone mark, variant type (SNV or indel), 
proximity to constrained (ExAC [36] pLI > 0.5) genes, and anchor to either transcription start 
site (TSS) or 3’ untranslated regions (3’UTRs). We determined the number of independent tests 
with eigenvalue decomposition and did a strict Bonferroni p-value adjustment using this value to 
correct for multi-testing [37]. The combination strategy is outlined in Figure 1.2a and yielded 
105 independent tests for a significance threshold of 4.76x10-4. 
 
1.2.5 Enrichment of de novo noncoding variants that potentially disrupt post-
transcriptional regulation in CHD 
 
We observed a significant enrichment of variants in RBP binding regions that overlap with 
H3K36me3 marks in CHD cases compared with controls, as shown in the volcano plot (Figure 
1.2b). The most significant test result is enrichment in cases of RBP variants with H3K36me3 
marks in UCSF4 stem cell tissue (OR=1.13, 95% CI 1.1-1.2, Fisher’s exact test 2-tailed 
p=8.77x10-5, 1672 case variants involved, Figure 1.2c). The signal was statistically significant 
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for multiple other embryonic stem cell types, as well as when limited to only constrained genes 
or to regions near transcription start sites. The intersection of these biologically relevant features 
yielded the largest statistically significant effect size (OR=1.3, 95% CI 1.1-1.5, p=2.68x10-4, 327 
case variants involved).  
 
Figure 1.2. Enrichment of variants in RNA-binding protein category annotations.                             
a) Five groups of annotations were defined to investigate post-transcriptional regulation through 
disruption of RNA-binding protein binding (i) variant type; (ii) region type; (iii) RBP category; (iv) gene 
sets, specifically pLI constraint on nearest gene; and (v) histone mark annotations for actively transcribed 
regions in relevant proxy tissues. Picking one annotation from each group resulted in 162 possible 
combinations. These annotation categories were considered in the category-wide association test and 
yielded 105 independent tests, giving 4.76e-04 as the strict Bonferonni threshold. b) Variant enrichment 
and significance for each test category, determined with a two-sided Fisher’s Exact Test (FET). The 
association tests passing Bonferonni significance have been highlighted in red. c) Tabulation of the 
highlighted (red) tests from panel (b), including FET 95% confidence intervals. 
* 8 embryonic stem cell (ESC) tissues, plus fetal heart tissue; all reasonable proxies for developing heart. 
 
1.2.6 Distribution of noncoding DNVs in canonical variant classes 
 
We characterized the distribution of DNVs across canonical variant classes (intronic, 
promoter, untranslated regions, etc.) for post-transcriptional regulatory-disrupting DNVs and 
  a)                                                                      b)                                          
 c)                                                             
                                          
 
a)                                                             b)                                          
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variants from the two transcriptional regulation-focused approaches highlighted in the paper 
(HeartENN-damaging score ≥ 0.1 DNVs, prioritized human fetal heart enhancer multiple-hit 
DNVs) (Figure 1.3). For DNVs not identified by any of the three bioinformatic methods, the 
majority were intergenic in both cases (52%) and controls (52%); in contrast, variants prioritized 
by the three methods were represented at higher proportions in introns, where both 
transcriptional and post-transcriptional regulation play a role. There was additional enrichment 
among other canonical categories depending on the method, with post-transcriptional DNVs 
specifically being over-represented in 3’UTR regions compared to the two transcription-focused 
methods. These findings provide additional evidence that the DNVs associated with CHD are 
more likely to have a functional impact, and that the three parallel approaches we used were all 
useful in implicating different categories of gene regulatory disruption. 
 
Figure 1.3. Fraction of DNVs in each of the canonical variant classes.                              
Region type fraction was calculated separately within CHD and unaffected SSC subjects for each of the 
three methods (including overlaps): 1. HeartENN-damaging (predicted score ≥ 0.1) DNVs, 2. prioritized 
human fetal heart enhancer multiple-hit DNVs, and 3. post-transcriptional regulatory-disrupting DNVs. 
The total number of variants in each group has been tabulated to the right of the figure. 




1.2.7 Recurrently implicated genes with noncoding DNVs 
 
We examined the nearest genes among the union of implicated noncoding DNVs 
(HeartENN-damaging DNVs [2238 cases, 4177 controls], prioritized human fetal heart enhancer 
multiple-hit DNVs [99 cases, 13 controls], and post-transcriptional regulatory-disrupting DNVs 
from all seven Bonferroni-significant enrichments [2149 cases, 3963 controls]). Twenty-five 
recurrently implicated genes were identified using a two-sided binomial test (p < 0.05) 
(Supplemental Table 16 in Richter, et al, 2020 [28]), and candidate genes of highest interest were 
identified by annotation with gene mutation intolerance metrics: ExAC [36] pLI > 0.5 or 
missense Z score > 3, high RNA expression rank in mouse E14.5 heart, membership in known 
human or mouse CHD gene sets, and membership in CHD-associated KEGG [38] pathways. The 
prioritized results included two known human CHD genes, although probands with those 
variants did not have the characteristic CHD phenotype of pulmonic stenosis. The top most 
notable candidate genes were SHOC2 (human CHD genes and constrained), ZNRF3, CPSF3 
(CHD-associated KEGG pathway and constrained), and MAP4K4 (96th percentile embryonic 
heart expression and constrained). 
 
1.2.8 Contribution to CHD 
 
We estimated the mean attributable risk to CHD in the exome-negative cohort across all three 
methods (see Methods 1.4.7), with the simplifying assumption that there was at most one causal, 
functional DNV per proband. Depending on the score cutoff chosen, HeartENN-damaging 
contribution range was estimated as 3-24%. On the other hand, DNVs in prioritized human fetal 
heart enhancers contributed to 12.1% of previously unexplained CHD in total, with 1.1% 
attributable to shared HeartENN ≥ 0.1 DNVs. When limiting prioritized human fetal heart 
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enhancer DNVs to those associated with genes having ExAC pLI > 0.5 or high embryonic mouse 
heart expression, the estimates were lower: 5.4% and 3.8%, respectively. This resulted in a final 
estimated contribution range of ~4-12%. Finally, the DNVs implicated in post-transcriptional 
disruption contributed to 10.0% of CHD in this cohort. Although the cumulative percentage 
mean attributed risk (17-45%) suggests a substantial contribution in WES-negative CHD, these 
estimates must be refined in future studies. In summary, the fraction of CHD with contributory 
noncoding predicted functional DNVs in this WES-negative cohort is at least as high as the 




Among many disorders with unexplained genetic etiologies, noncoding variants in aggregate 
are a potentially huge contributor to disease. Using Whole Genome Sequencing, we investigated 
this hypothesis with a systematic examination of noncoding, putative regulatory elements in a 
mutation-negative CHD cohort. We, like other researchers [37, 39-41], observed a lack of 
significant findings across broad noncoding annotation categories. However, in contrast, our 
alternative interrogation strategies of prioritized noncoding variants provided evidence for 
noncoding DNVs in CHD pathogenesis. 
HeartENN, which provided variant-level scores, similar to the multifaceted DeepSEA 
algorithm that uncovered noncoding DNVs in autism [42], defined significantly more DNVs in 
CHD probands with putative functional effects. Separate analyses of prioritized human fetal 
heart enhancers identified distinct and some overlapping DNVs in CHD cases. Notably, 
functional assays were positive when these two strategies were combined. Although there was no 
category-wide burden for DNVs in transcriptional regulation, we did observe Bonferroni-
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significant category-wide burden among RNA-binding protein binding sites restricted to regions 
with a plausible role in heart development (with the biggest enrichment observed in stem cells). 
Together, these results implicate a role for noncoding DNVs in CHD at both the transcriptional 
and post-transcriptional regulatory levels. Overall, our ability to detect signals was strongly 
influenced by the existence of specific information about noncoding genomic regions relevant to 
cardiovascular development, effectively allowing us a narrower search space in which to 
interrogate DNVs. 
Through considering the union of transcriptional and post-transcriptional variants, we 
identified both known and potential human CHD genes. The regulatory regions of SHOC2, 
CPSF3, ZNRF3, and MAP4K4 are of particular interest, and are prime candidates for future CHD 
studies. Our findings were the first to systematically associate human CHD with cardiac 
regulatory DNVs, and highlight the potential of WGS to more fully elucidate the genetic 
architecture of developmental disorders. Extension of the statistical framework used is likely to 
define additional noncoding variants in CHD. When applied to larger cohorts, we expect to 
refine the magnitude of noncoding effects and to investigate complex CHD genetics, such as 
epistatic and pleiotropic effects of noncoding and coding variants. 
The variant prioritization schema used in this study was based on gene-level properties like 
mutation constraint and manual review of previous results from the literature; approaches like 
our combinatorial burden multi-testing framework could only implicate group enrichment rather 
than explain the impact of specific variants within those groups. My later work for this 
dissertation would seek to model specific RBP binding processes to be able to make true variant-
level predictions and be able to identify the specific variants among these implicated sets that 
actually drive post-transcriptional regulatory disruption and could have a causal link to CHD. 
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Pediatric Cardiac Genomics Consortium (PCGC): Patients with structural CHD and their 
parents (n=763 trios) were enrolled in the PCGC's Congenital Heart Disease Network Study 
(CHD GENES: ClinicalTrials.gov identifier NCT01196182) [25]. The protocols were approved 
by the Institutional Review Boards of Boston’s Children’s Hospital, Brigham and Women’s 
Hospital, Children’s Hospital of Los Angeles, Children’s Hospital of Philadelphia, Columbia 
University Medical Center, Great Ormond Street Hospital, Icahn School of Medicine at Mount 
Sinai, Rochester School of Medicine and Dentistry, Steven and Alexandra Cohen Children’s 
Medical Center of New York, and Yale School of Medicine. All subjects or their parents 
provided informed consent. Individuals with a chromosomal aneuploidy, copy number variation 
associated with CHD, or likely causal variant (WES-identified) were excluded. Echocardiogram, 
catheterization, and operative reports were reviewed to determine cardiac phenotypes. 
Extracardiac structural anomalies were obtained from the medical records. Patients were 
classified as having neurodevelopmental disorders (NDDs) if parents reported the presence of 
developmental delay, learning disability, mental retardation, or autism for subjects at least 12 
months old. 
Controls: Controls comprised 1611 CHD- and autism-unaffected sibling-parent trios derived 
from sporadic autism quartets that consisted of one offspring with autism, one unaffected sibling, 
and their unaffected parents [27]. Controls were ascertained from 1627 siblings after excluding 
16 with a past medical history including congenital heart disease. The Simons Foundation kindly 




1.4.2 Whole genome sequencing and variant identification 
The DNAs of the PCGC samples were sequenced at the Baylor College of Medicine 
Genomic and RNA Profiling Core (n=900), the New York Genome Center (NYGC) Genomic 
Research Services (n=75), and the Broad Institute for Genomic Services (n=1314) following the 
same protocol. Genomic DNAs from venous blood or saliva were prepared for sequencing using 
a PCR-free library preparation (n=2289) or SK2-IES library preparation (n=75, Broad). All 
samples were sequenced on an Illumina Hi-Seq X Ten with 150-bp paired reads to a median 
depth >30x per individual. The controls were prepared similarly to cases. Specifically, the 
controls were sequenced at NYGC (n=4833) with 150-bp paired reads and median depth >30x 
per individual, using either a PCR-based library preparation on an Illumina Hi-Seq 2000 (n=114) 
or a PCR-free library preparation on an Illumina Hi-Seq X Ten (n=4719). Previous Simons 
Simplex Collection sequencing of controls was performed at NYGC on the Illumina Hi-Seq 
2500 (n=120) or Illumina Hi-Seq X Ten (n=4761) to >30x coverage with 150-bp paired reads. 
For both cases and controls, reads were aligned to GRCh37 or GRCh38 with the Burrows-
Wheeler Aligner (BWA-MEM)[43]. GATK Best Practices recommendations were implemented 
for base quality score recalibration (QSR), indel realignment, and duplicate removal [29, 44] 
Standard hard filtering parameters were used for SNV and indel discovery across all 763 PCGC 
and 1611 control trios, followed by N+1 joint genotyping and variant QSR [45, 46]. 
 
1.4.3 Identification and confirmation of de novo variants 
De novo variant (DNV) identification was performed for both cases and controls by pooling 
three pipelines from PCGC members at Mount Sinai, Columbia and Harvard. Mount Sinai used 
two tiers, a high stringency tier and a low stringency tier. High stringency tier parameters were 
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GATK PASS (i.e., variants classified as true with an adaptive error model based on known true 
sites and artifacts), heterozygous ratio (AB) set to 0.3-0.7 in the proband, homozygous ratio 
(AB) less than 0.01 in both parents, depth (DP) ≥ 10, Joint Genotyping allele count (AC) = 1 
across all trios, Genotype Quality (GQ) > 60 (proband and parents), Alternate Allele Depth 
(AAD) > 7 in the proband, and AAD < 3 in each parent. The lower tier consisted of de novo 
calls falling outside of the higher tier that did not fail the following filters: GATK PASS, 
heterozygous AB set to 0.2-0.8, DP 7-120, AC = 1 in all trios, GQ > 60 (proband), GQ > 30 
(parents), AAD > 7. At Columbia, the parameters we used for DNV identification were 
heterozygous or homozygous for the alternate allele in the proband, homozygous for the 
reference allele in the parents, not in a multiallelic site (3 or more), AC ≤ 2 in the cohort, 
Fisher's exact test strand bias (FS) < 25, variant quality by depth (QD) > 2 for SNVs and QD > 
1 for indels, ReadPosRankSum > -3 for indels, proband genotype Phred-scaled likelihood (PL) 
≥ 70, proband AAD ≥ 6, proband heterozygous AB ≥ 0.28 if AAD ≥ 10 or heterozygous AB ≥ 
0.20 if AAD < 10, parental GQ ≥ 30, parental DP ≥ 10, parental AB < 0.035, and population 
frequency < 0.1% (1KG, ESP, ExAC). For the third pipeline at Harvard, the parameters were 
AC = 1, DP 7-64 inclusive, ADD ≥ 5, heterozygous AB 0.2-0.8 inclusive, homozygous AB ≤ 
0.1. Putative de novo calls near indels, in a homopolymer indel, or in a dinucleotide repeat were 
subsequently visually filtered with IGV.  
After consolidating de novo calls, all variants were force called with FreeBayes [30]. GATK 
and FreeBayes both perform local realignment. GATK uses a combination of known common 
variants, indels, and entropy calculations to generate log of the odds ratio (LOD) scores for 
alternative consensus sequences, replacing original alignments if LOD scores are higher. 
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FreeBayes generalizes this Bayesian caller approach to allow for multiallelic loci and non-
uniform copy number across samples, and the combination of GATK and FreeBayes variant 
calling was previously reported to improve the positive predictive value of indel identification 
to >97%. Therefore, FreeBayes variant calling was performed on GATK-identified de novo 
variants to reduce false-positive variants. DNVs in Sinai's high evidence tier but false with 
FreeBayes were manually reviewed. Finally, IGV plots of all the putative DNVs were passed 
through an 8-layer convolutional neural network trained on curated IGV plots [31], and 
classified into 6 categories (de novo SNVs, de novo insertions, de novo deletions, complex, 
uncertain, and false positives). Predicted false positives were excluded. Predicted de novo 
insertion, deletion, complex and uncertain events were subject to further manual inspection to 
remove additional false positives. DNVs with ExAC allele frequency > 0.1% as well as DNVs 
in nonstandard chromosomes, segmental duplications (score ≥ 0.99), low complexity regions, 
low mappability (300 bp, score < 1) regions, mucin or HLA genes, and ENCODE blacklisted 
sites were removed [46-49]. Finally, all DNVs within 50 bp in the same proband were 
considered a single event (i.e., a mutation cluster) for region-based and multiple-hit enrichment 
tests. DNVs identified using GRCh37 were lifted over to GRCh38. Sanger sequencing 
validation was performed for 266 de novo SNVs and 83 de novo indels. 
 
1.4.4 Annotations and gene sets 
Variants were annotated using ANNOVAR (v2017-07-17). The three gene sets used in this 
study were genes in which coding mutations cause isolated or syndromic CHD in humans 
(human CHD genes), genes for which mouse knock-downs or knock-outs are associated with 
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CHD (mouse CHD genes), and the top quarter of expressed genes during heart development 
(high heart expression, HHE genes) [9, 26]. To generate the mouse CHD gene set, mammalian 
phenotype ontology (MPO) terms potentially relevant to CHD were identified. These were 
reviewed to remove cardiovascular terms not specific to CHD, such as cardiac 
dilation/hypertrophy, arrhythmias, and coronary artery disease [50]. Data on the mouse strains 
associated with these MPO terms were downloaded from 
http://www.mousemine.org/mousemine/. Only single-gene transgenic mutant mouse strains 
were kept, and these mouse genes were converted to their human orthologs 
(ftp://ftp.informatics.jax.org/pub/reports/HOM_MouseHumanSequence.rpt). 
 
1.4.5 Multiple hypothesis testing correction for combinatorial test 
The p-value threshold was determined by correcting for the number of independently tested 
hypotheses. Because the 162 noncoding features were highly correlated, the number of 
independent hypothesis tests was set as the number of eigenvectors that explain ≥99% of the 
variance in the correlations between the features, similar to the approach described in Werling, et 
al., 2018 [37]. A p-value was simulated for all pair-wise correlations between features. The p-
value is equal to the fraction of 10,000 permutations with a more extreme correlation than 
observed, calculated based on the overlap between de novo variants (DNVs) and features. For 
each permutation, a random feature overlap matrix was generated by treating the observed 
overlaps as random variables and sampling from a binomial distribution. Eigenvalue 
decomposition of these p-values was used to estimate the number of effective tests that explain 
≥99% of the variance in the 162 features. For the 162 features, this corresponded to 105 
independent, effective tests and thus a Bonferroni p-value of 0.05 / 105 = 4.76x10-4. 
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1.4.6 RNA binding protein eCLIP binding data 
Raw eCLIP binding data for the 160 available RNA binding proteins were obtained from 
ENCODE [22]. Peaks were called from replicates using CLIP Took Kit (CTK) [35] and further 
processed [51] into a narrower, higher confidence set of binding regions for each RBP. All peaks 
were then given 50 base pair padding on both sides to expand the genomic coverage and increase 
the number of variants associated with each RBP. 
 
1.4.7 Analysis of disruption of post-transcriptional regulation 
Five groups of annotations were defined to investigate post-transcriptional regulation through 
disruption of RNA-binding protein binding: (i) 3 variant types (SNV, indel, all); (ii) 3 region 
types (TSS ± 20 kb region anchor where TSS is gene transcription start sites, 3’UTR region 
anchor defined as [TES – 5 kb, TES+20 kb] where TES is gene transcription end sites, no region 
restriction); (iii) 1 RBP category (union of eCLIP peaks from 160 RBPs, padded on both sides 
with 50 bp); (iv) 2 gene sets (unconstrained or pLI > 0.5 constraint on nearest gene); and (v) 
histone mark annotations for actively transcribed regions in relevant proxy tissues, specifically 
H3K36me3 in eight human embryonic stem cell tissues: ES-I3 stem cells (E001), ES-WA7 stem 
cells (E002), H1 stem cells (E003), H9 stem cells (E008), HUES48 stem cells (E014), HUES6 
stem cells (E015), HUES64 stem cells (E016), ES-UCSF4 stem cells (E024); plus human fetal 
heart tissue (E083).  
Histone modification peaks were downloaded as broadPeak files, originally determined from 
Roadmap Epigenomics ChIP-Seq [52]. Raw broadPeaks were preprocessed to include the 
majority of the area between the 5’ and 3’ UTRs for transcribed genes and smoothen noise in 
identifying actively transcribed regions in proxy tissues: specifically, gaps under 1 kb between 
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histone peaks here were filled, giving improved signal for genes with many peaks throughout. 
Picking one annotation from each group resulted in 162 possible combinations. These 
annotation categories were considered in the combination-wide association test and yielded 105 
independent tests, giving 4.76e-04 as the strict Bonferroni threshold. Two-sided Fisher’s exact 
tests were used to obtain odds ratios and associated p-values for all test combinations. DNVs 
within RefSeq protein-coding exons were excluded. 
 
1.4.7 Calculation for attributable risk 
The fraction of CHD cases that are attributable to noncoding DNVs was calculated by 
determining the excess fraction of DNVs in cases compared to those in controls (Equation 1.1).  
 
Equation 1.1. Excess fraction of DNVs in cases compared to those in controls 
 
We then assumed at most one contributory DNV per proband (simplifying assumption, 
giving an upper bound) to calculate the attributable fraction (Equation 1.2).  
 
Equation 1.2. Attributable fraction calculation 
 
This attributable risk (AR) was calculated for HeartENN-damaging DNVs at successively 
stringent thresholds, DNVs within prioritized human fetal heart enhancers in multiple gene sets, 
and DNVs shared between these transcription-focused results and DNVs implicated in the top 
RBP enrichment. The AR is cumulative across methods (after subtracting out contribution of 
shared DNVs) and represents an estimate that should be refined in future studies. 
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Chapter 2: POLARIS - Modeling RBP Binding to RNA transcripts 
In this section, I describe POLARIS (Prediction Of Localized Affinity for RBPs In 
Sequence), a new deep-learning method for predicting site-specific binding affinity of RNA-
binding proteins (RBPs) to the transcribed genome. The POLARIS model has two modules: 1. a 
convolutional neural network (CNN), trained on RBP enhanced crosslinking and 
immunoprecipitation (eCLIP) sequence data to predict overall RBP binding within a transcript 
region, and 2. a Gradient-weighted Class Activation Mapping (GradCAM) implementation to 
identify individual positions that are informative for binding prediction in the region. POLARIS 
outperforms previously published models trained on the same data sets and achieves a median 
area under the receiver operating characteristic curve of ~ 0.96 for 160 RBPs across three 
different cell lines. When trained with a sufficiently large sequence context of 1 Kbp, the 
convolutional neural network architecture utilized by POLARIS implicitly captures the 
contribution from RNA secondary structure to binding affinity. Finally, the GradCAM module 
generates RBP binding signal at single base pair resolution similar to binding motifs. With 
localized prediction, POLARIS is especially well suited for in vivo binding interpretability and 























Recently several studies have shown that post-transcriptional regulation acts as a major link 
between rare noncoding variants and human disease [9, 11, 18]. Post-transcriptional regulation is 
mediated by interaction of RNA-binding proteins (RBPs) and messenger RNAs. Leveraging 
RBP-RNA interaction can help to improve the interpretation of noncoding variants in disease 
studies. However, our current understanding of the impact of genetic variation on RBP-RNA 
interaction is limited due to the complex nature of RBP binding: although RBP binding is 
foremost driven by biochemical recognition of specific sequence motifs, many other factors such 
as RNA secondary structure also contribute. Indeed, most motifs [24] still remain unknown due 
to limited in vivo binding data, variability in RBP motif strength, and a complicated relationship 
between raw sequence and true biological binding of RBPs: mere presence of a motif alone does 
not guarantee binding at a genomic site in a particular tissue. Therefore, to fully understand the 
effects of rare noncoding variants in post-transcriptional regulatory regions, it is first critical to 
model underlying RBP binding with greater accuracy. 
In the past few years, large efforts such as the ENCODE (Encyclopedia of DNA Elements) 
project [22] have performed eCLIP (enhanced crosslinking and immunoprecipitation) 
footprinting experiments to capture in vivo binding of RNA binding proteins, allowing us to 
perform large-scale genomics data analyses [23]. Additionally, significant advancements in deep 
learning have provided us with powerful computational tools to solve complex pattern 
recognition problems. Current transcription factor (TF) and RBP binding models such as the 
DeepSEA/SeqWeaver [32, 42] and DanQ [53] models have seen initial success in modeling 
binding to sequence using deep neural network architectures. Other models like LS-GKM [54], 
which evolved from the original gkm-SVM [55] model, have leveraged more conventional 
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machine learning techniques such as support vector machines (SVMs) to predict RBP binding 
affinity. However, all of these models have gaps in several important areas: Firstly, in the case of 
the conventional machine learning models, there is typically too much focus on optimal k-mer 
sequence matching; this can entirely miss distributed recognition scenarios involving multiple 
nearby weaker binding motifs, and fails to account for distal factors affecting binding in vivo. 
One example was highlighted by mCross [51], which combined k-mer matching with precise 
crosslinking position registration and showed that SRSF1 can often recognize clusters of GGA 
half sites in addition to its canonical GGAGGA motif; these cases of weak motif clusters are 
difficult to capture with a singular k-mer focus. Secondly, when the feature set is extremely large 
and network architecture extremely deep or complex, as in the case of many popular neural 
network models, there is a frequent danger of lessened model interpretability. And thirdly, model 
predictions tend to be only for presence of binding within a region, with any possible 
downstream localization scripts being inefficient and slow to use to generate localized RBP 
binding maps at large scale.      
Here we describe POLARIS, an integrated convolutional neural network (CNN) model that 
utilizes not only sequence context, but also target gene expression levels and regional transcript 
annotation in order to generate a more accurate model for RBP binding prediction. By 
incorporating these additional factors into the feature set and simplifying the network 
architecture, POLARIS is able to reach excellent validation set performance while remaining an 
interpretable and biologically grounded model. Finally, the built-in GradCAM module allows 
localization at single bp-resolution of the RBP signal on the original input sequence, in a way 






2.2.1 Binding model structure and predictors 
 
POLARIS utilizes a convolutional neural network (CNN) as the engine to drive its sequence 
pattern recognition module. CNNs were originally designed for computer vision tasks such as 
handwritten digit interpretation [56-58], and more recently have been applied with success in 
many areas of genomics and structural biology. The principle use of convolutional layers is their 
capability to extract hierarchical features, or nonlinear spatial local patterns, from images or 
sequence data. In effect, successive layers perform new feature creation using the feature set of 
the previous layer’s nodes, with the final layer determining a prediction based on advanced 
compound features.  When building a modern CNN, each convolution layer is typically 
immediately followed by a ReLu Activation function, which adds nonlinearity and sharpens 
features with positive predictive values, Max Pooling, which adds shift invariance and helps 
computability [59], and random Dropout, which acts to regularize the training process. Model 
weights and biases are all updated each epoch in the training process via backpropagation, which 





Figure 2.1. POLARIS model architecture 
The binding module uses a classic two-layer convolutional neural network (CNN) structure, with max 
pooling and dropout layers after each convolution, and eventual integration of transcript region type 
annotation and nearest gene expression before the final Sigmoid binding output. The GradCAM 
localization module calculates the gradient of each convolutional filter with respect to this output, and 
maps the bp-specific contribution to the output of each position in the input sequence. In other words, it 
highlights the RBP binding motif(s) driving recognition of the full window as a binding region for a 
particular RBP. 
 
POLARIS’ design follows this classical convolutional neural net framework: the first set of 
convolutional and max pooling layers serve to learn precise sequence motifs, while the second 
set of layers captures overarching patterns in the sequence (Figure 2.1). Max pooling and 
Dropout, as well as L2 regularization within the convolutional layers, are used to generalize 
training and make the model more robust. Because presence of a sequence-binding motif alone is 
insufficient to indicate RBP binding in tissues where the gene is not expressed - RBPs only bind 
to certain genes in certain tissue contexts - gene expression level is used to help guide the 
likelihood of actual RBP binding in vivo. On the other hand, inclusion of transcript regional 
annotation data takes advantage of the varying sequence properties at different regions of the 
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transcript: for example, GC content of 5’UTR regions is typically higher than that of 3’UTR 
regions [61], which can heavily influence motif recognition and RBP binding affinity. 
  
2.2.2 Model training and evaluation 
 
POLARIS was trained using eCLIP RBP assay peaks, taken from ENCODE database.14 
RBPs generally had ≫10k peaks each, a large enough N to suggest feasibility of deep learning 
(Figure 2.2).  
 
Figure 2.2. Histogram of eCLIP peak count per RBP. 
The majority of RBPs had N ≫ 10k peaks, indicating plausibility of applying deep learning. 
 
These peaks were further processed with CLIP Tool Kit (CTK) [35] into narrower, higher 
confidence sets of in vivo binding sites for each RBP; these positive training data regions indicate 
true RBP binding either within or close to them. Finally, the regions were padded (equally) on 
both sides to 1kb total sequence length, to be able to learn binding effects from reasonably distal 
32 
 
sequence elements. Negative sequences for each RBP were sampled at random from transcribed 
regions of the genome, under the constraint that the overall GC content distribution of the 
negatives match that of the corresponding positives (Figure 2.3).  
 
Figure 2.3. Comparison of GC content distributions  
Regional GC content distributions are shown for both the positive (eCLIP) dataset (a), and the 
sampled negative (random transcribed regions) dataset (b). GC distribution is intentionally matched 
in the training data (for each RBP binding model), to not accidently train this feature. 
 
In addition to genomic sequence inputs, POLARIS also includes input channels for target 
gene expression levels of the corresponding cell type where the eCLIP sequence data was 
generated, and transcript regional annotation type (3’UTR, 5’UTR, introns, exons, promoters, 
proximal 1-5kb intergenic sequence, or no annotation) of each sequence.  Regional annotation 
type was determined by the longest transcript in the given region from GENCODE, and the gene 
expression data is logscale transcript parts per million (TPM) values from the RNA-seq data by 
ENCODE. We used all of these inputs to train POLARIS on 112 unique RBPs from the adrenal 
gland, HepG2, and K562 cell lines, for a total of 160 separate RBP models (if a RBP had data 
from multiple cell lines, they were trained and considered separately). 
 We randomly partitioned the eCLIP data to training (80%) and testing (20%), with balanced 
positives and negatives. During training, we used five-fold cross-validation to evaluate models 
for each RBP. The binding model with the highest mean AUC in cross-validation was selected as 
a)                                                                   b)                                          
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the optimal model for each RBP. Same-cell model AUCs referenced in this paper refer to 
validation set performance of these final RBP models for the most fair and generalizable metric. 
The POLARIS model was implemented in Tensorflow 2.2 with Keras API, with the entire 
training process taking around 5-10 min per RBP on an NVIDIA GTX 1080 GPU with 2560 
cores and 8 GB memory. 
 
2.2.3 Performance of POLARIS in predicting RBP binding affinity  
 
We find that POLARIS is able to successfully predict binding, with a median area under the 
curve (AUC) of 0.957 across all 160 RBPs analyzed (validation set, 5-fold CV, same-cell). To 
understand performance variance across RBPs, we plotted the distribution of binding prediction 
AUCs for these 160 RBPs (Figure 2.4a). As expected, POLARIS’ model performance improves 
as the sample size for an RBP increases (Figure 2.4b).  
A major goal of POLARIS is to predict cell-type specific RBP binding. To evaluate this, we 
tested the trained models for each given RBP across cell lines. For example, we trained a QKI 
binding model on data from the HepG2 cell line, then tested the model using data from the K562 
cell line, and vice versa. POLARIS was still able to achieve a high AUC of 0.942 using cross-
cell method of validation (Figure 2.4c, first two rows). As a baseline method, we used the eCLIP 
sites from one cell line (HepG2, K562) to directly predict binding in the other - without any 
actual neural network training - to see how much inherent overlap there was in the binding 
peaks. The final row of Figure 2.4c shows that this baseline method performs poorly, with a 




                
 
Figure 2.4. Performance of POLARIS on predicting RBP binding affinity using in-cell 
5-fold cross validation.  
a) Density distribution of area under receiver operating characteristic curves (AUC) for each 
RBP binding prediction across all 160 RBPs.  
b) AUC of each RBP plotted against its respective sample size in log scale. 
c) Comparison of in-cell vs. cross-cell comparisons (first two rows). The final row “No 
Training” shows cross-cell accuracy with a naïve baseline model (negative control) that 
predicts K562 binding status exactly from HepG2 (and vice versa). 
 
 
2.2.4 Evaluation of POLARIS’ framework and feature capture 
 
When designing the model framework for POLARIS, we saw that including features based 
on prior knowledge of biological mechanisms, such as target gene expression and transcript 
regional annotation categories, boosted model performance (Figure 2.5a). Addition of the 
regional annotation feature to the base CNN model increased median AUC from 0.899 to 0.932. 
Alternatively, addition of gene expression values increased median AUC from 0.899 to 0.945. 
a)                                                  b)                                          
c)                                                                                    
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The best validation set performance was achieved with inclusion of both features (median AUC 
= 0.957), which is the setup used in the final POLARIS model.  
 
  
Figure 2.5. Evaluation of POLARIS model features and secondary structure impacts 
a) RBP binding prediction improves when explicitly adding gene expression and transcript 
annotation information as inputs. The final binding prediction model used in SUPRNOVA 
incorporates both gene expression and annotation inputs. 
b) Performance (measured as AUC) when including secondary structure context (hairpin loop, 
internal loop, etc.) is slightly improved when the input sequence length is small. This is indicated 
by a shallower slope than 1 for the red 10bp line. However, once the input sequence length is 
increased, included secondary structure information no longer affects POLARIS’s performance. 
 
 
2.2.5 Effects of adding predicted secondary structure of mRNA 
 
RNA secondary structure is a major factor of binding affinity of certain RBPs [62]. We 
followed a technique presented in Koo et al. [63] to investigate if including secondary structure 
information as input can improve binding prediction. After using RNAplfold [64] (with Kazan, 
H.’s modified script [65]) to annotate sequences with predicted secondary structure information, 
we fed this information into our model as an additional input channel (similar to the channels for 
gene expression and regional annotation). Simpler, motif-only models such as PWMs, k-mer 
SVMs, and small-window neural networks see a boost in prediction performance with addition 
of secondary structure feature [63, 65, 66]. Indeed, even POLARIS saw a performance boost 
a)                                                                        b)                                          
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with RNAplfold when limited to a more narrow 10bp window size. However, inclusion of these 
structure profiles did not boost the performance of the POLARIS models with sufficiently large 
input sequence length (Figure 2.5b). 
 
2.2.6 Comparison with other methods 
 
Besides a standard CNN, a recurrent neural network (RNN) hybrid model was also 
considered for the core POLARIS framework. Based on the work of Quang et al. [53], which 
highlighted the potential benefits of long short-term memory (LSTM) layers, we tested a CNN-
LSTM hybrid version of POLARIS that replaced the second convolutional layer with an LSTM 
layer. The input data was exactly the same as what we had used to evaluate the CNN 
architecture; however, despite taking longer to train, this hybrid model did not provide any 
performance gain, only achieving median AUC of 0.933. 
 POLARIS outperforms previously published methods such as the gapped k-mer based SVM 
model, LS-GKM (from Lee, D. et al. [54], based on the original gkmSVM [55]), and the 
standard CNN-based DeepSEA model from Olga Troyanskaya’s group [42] that Seqweaver 
utilizes for its post-transcriptional modelling. After re-training these methods from scratch using 
the same input data as POLARIS and performing 5-fold cross validation, Seqweaver achieves a 
median AUC of 0.871, and LS-GKM reaches a median AUC of 0.892 (Figure 2.6a). This is more 
comparable to the performance of our basic model framework, which did not include expression 
or annotation data. We also tested a version of Seqweaver into which we integrated our exact 
expression and region type tensors used in POLARIS (labeled “Seqweaver+” in Figure 2.6a). 
This brought results significantly closer (median AUC = 0.931), but overall POLARIS was still 
more consistent and had higher average performance (median AUC=0.957). We show RBP-
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specific results for three examples: RBFOX2, ILF3, and QKI, with each trained in HepG2 and 
tested in K562 (Figure 2.6b,c,d). In ILF3 and QKI in particular, each with N ~ 30k eCLIP peaks, 
we see some of the most significant performance improvements over the competing models.  
 
 
                                  
 
Figure 2.6. Performance of POLARIS compared to other computational methods for predicting 
RBP binding affinity 
a) Violin plot showing distribution comparison of all methods’ cross-cell performance results. 
Depending on the RBP, cross-cell performance of Seqweaver + expression + region type annotation 
got near POLARIS, but overall POLARIS was more consistent and had higher average performance. 
b,c,d) Specific examples for RBFOX2, ILF3, and QKI, respectively: all were trained in HepG2 and 
tested in K562. In ILF3 and QKI in particular, each with N ~ 30k eCLIP peaks, we see some of the 
best performance improvements over the competing models. 
 
 
2.2.7 GradCAM results for determining localized affinity and motif discovery 
 
Finally, we use gradient-weighted class activation mapping (GradCAM)[67] algorithm to 
localize sites in the original input sequence that are informative for binding prediction (Figure 
2.1). Class activation mapping (and GradCAM in particular) were also originally developed for 
c)                                    ILF3                               d)                          QKI                     
a)                                                                       b)                        RBFOX2                       
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image recognition tasks; however, like CNNs themselves, the algorithms translate very well to 
the case of binding motif modeling on 1-dimensional sequence. GradCAM allows our 
localization implementation to be mathematically efficient, requiring only the one original pass 
through the network per input. It can thus be run at large scale to generate fine-tuned binding 
maps for all available RBPs at once.  
GradCAM is a method to produce a coarse localization map highlighting the important 
regions in the input image/sequence for predicting the concept class (specific RBP binding, in 
our case). Given an input image/sequence, the method captures the outputted feature map of the 
convolution layer and weights every filter in that feature map by the gradient of the class with 
respect to the filter. Intuitively, filter activation is balanced by the importance of each filter to the 
output class, and this weighted sum creates a spatial map of class activation by the input: we can 
then interpolate/stretch the resulting heatmap to original input size and overlay onto the 
image/sequence. In other words, GradCAM allows us to robustly highlight the causal subsections 
of input regardless of how many layers the model contains or how the neural network 
architecture is set up. In our case of 1-dimensional convolution to learn RBP genomic binding 
motifs, the highlight represents the portion of the input sequence that is likely bound by the 
specific RBP. 
We implemented the GradCAM algorithm as a single reverse pass once the binding module 
determines a prediction. Recovery of canonical motifs, for two representative examples (RBPs 
RBFOX2 and EFTUD2), are shown in Figures 5a,b. We qualitatively compared the highest 
activating regions for each RBP’s sequences to their respective known canonical motifs (based 
on mCrossBase[51]), and found a high recovery of known motifs, as well as plausible novel 




Figure 2.7. Recovery of canonical motifs using POLARIS’ GradCAM module.  
Shown are heatmaps for two representative RBPs: RBFOX2 (a) and EFTUD2 (b); sequence is 
shown in multiple rows for visibility, but are 1-dimensional character strings. Canonical binding 
sites and sequence logos have been taken from mCrossBase. 
 
2.2.8 Investigating strong POLARIS performance for weak motifs with GradCAM 
 
It is natural that POLARIS performs well when trained on RBPs whose binding motifs are 
especially consistent and clear to separate from surrounding genomic sequence. Thus, a naive 
expectation could be that validation AUC positively correlates with information content of 
sequence logos, a proxy of motif quality. The information content for each RBP was calculated 
by considering the top ten strongest motif versions most associated with the given RBP; we 
obtained these from mCrossBase database, which makes accessible results from the 
aforementioned mCross paper [51]. In order to obtain a single information content metric for 
each RBP, we selected the maximum total information content value (summed across positions) 
out of all of the candidate motifs.  
However, when we made a scatterplot of this relationship (Figure 2.8a), we found an 
observation of POLARIS’ performance that was not trivial to explain: although the general 
positive correlation trend was confirmed, there was a group of RBPs in the top-left corner with 
a)                                                                 b)                                          
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low motif information content that nevertheless had very strong performance (arbitrary AUC 
threshold >0.95 and AUC/IC ratio of .09; highlighted in red). 
                                                                
Figure 2.8. Investigating strong POLARIS performance for weak motifs 
a) AUC of each RBP plotted against the information content for each given RBP’s binding 
canonical binding motif, taken from mCrossBase. Highlighted in red are the weak motifs that still 
have very strong performance (AUC threshold >0.95 and AUC/IC ratio of .09) 
b) Density of diffusion/entropy for red RBP models vs. black ones, using the same color scheme as 
panel (a): weaker motifs generally do have more spread of binding score in the window, indicating 
multiple binding sites in the region. 
 
Our working hypothesis to explain this was that RBPs with weaker motifs could have 
multiple binding sites per binding window, to raise the total regional information content and 
enable post-transcriptional regulatory control with the same level of precision as RBPs with 
strong motifs. It was previously shown that this could be the case in the mCross paper [51], 
which found that the RBP SRSF1 can recognize clusters of GGA half-sites in addition to its 
canonical GGAGGA motif. We investigated the over-performing (red) RBP models by 
considering density of diffusion/entropy for them vs. the other (black) ones. Diffusion was 
calculated by averaging the Shannon’s entropy of the GradCAM heatmap output for each of the 
known positive eCLIP binding sequences, and then normalizing each sequence’s entropy by its 
a)                                                            b)                                          
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respective sequence POLARIS output score in order to focus only on capturing motif diffusion. 
We found that weaker motifs generally did have more spread of binding score in the window, 
with a clear enrichment of their RBPs at higher diffusion values (Figure 2.8b). This indicates 
multiple binding sites in the region, and confirms the plausibility of our hypothesis.  
 
2.2.9 Clustering GradCAM heatmaps to binding motifs and valleys 
 
We developed a weighted hierarchical clustering algorithm to automatically identify motifs 
and motif valleys from GradCAM heatmaps. Notably, our approach does not rely on fixed 
hyperparameter constraints on optimal motif length k or the number of motifs within a window, 
which can both strongly differ across RBPs and binding regions. We first create a pairwise 
distance matrix D that is the weighted sum of two distinct distance matrices: a) Score distance, 
where score is the GradCAM projection score ϵ (0,1) at every position, and b) Sequence 
distance, which is simply the base pair gap between every pair of positions. The relative impact 
of each of these matrices on D is controlled by a weight parameter α, helping guide the function 
to select motifs of reasonable length (higher α prioritizes score similarity over sequence 
proximity, encouraging consideration of longer motifs). An example distance matrix calculation 
for heatmap vector [1,1,1,0,0,0,1,1,1] and balanced α = 0.5 is shown below (Equation 2.1).
 




We then perform hierarchical clustering on D, producing a hierarchical tree; we found the 
results were most consistent when complete / furthest neighbor clustering was used, but the 
provided algorithm function supports average distance / UPGMA (unweighted pair group 
method with arithmetic mean) or any other distance aggregation function as well. We cut the tree 
at a fixed height h to obtain sequence clusters C. Finally, we find aggregate cluster scores S for 
each c ϵ C by averaging member scores within each cluster, and designate the clusters where S > 
m as RBP binding motifs; the remaining clusters represent connected valleys between motif 
plateaus.  
An h of 1 represents a furthest score distance of ~1 between directly neighboring clusters for 
the case of α = 0.5, and worked well in practice for a wide range of α up to 0.9. We also 
recommend binding threshold m > 0.5, which can be increased further to prioritize specificity 
over sensitivity in motif discovery. Using this hyperparameter selection, we ran our algorithm on 
eCLIP-positive validation set regions. Qualitatively, although resolving borderline cases with 
low POLARIS binding prediction scores was difficult, when binding prediction score was high 
(generally >0.5), the clustering worked very well to extract motifs; we show an example for the 




Figure 2.9. GradCAM heatmap clustering example for QKI   
Hierarchical clustering breakdown of a QKI GradCAM heatmap (POLARIS prediction score 0.629), for a 
region containing chr10:112708640 C→A mutation. This variant was highlighted in our earlier CHD 
WGS study described in Chapter 1, as its genomic location is near the known (and recurrently hit) CHD 
gene SHOC2; it is also tabulated as part of our analysis below in Table 2.1. The automatically extracted 
QKI binding motif UA*UAA (before a less confident U/CAUU) is a good match to the canonical 
sequence logo pictured in the top right (taken from mCrossBase, as in Figure 2.7). Clustering parameters 
used were score (vs. sequence proximity) weight α = 0.9, hierarchical tree cut height h = 1, and motif 
designation threshold m = 0.5 parameters. 
 
 
2.2.10 Application of POLARIS to Whole Genome Sequencing data 
 
Lastly, we re-applied POLARIS back to our analysis of congenital heart disease (CHD), 
where we had previously used a combinatorial multi-test framework with Bonferroni correction 
to search for case:control burden of relevant RBP binding sites (Richter, Morton, Kitaygorodsky, 
et al., 2020) [28]. In that analysis, we had discovered evidence of post-transcriptional 
contribution to disease, particularly by variants in several statistically enriched RBP annotation 
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subsets, but lacked a powerful method at the time to more deeply investigate which specific ones 
were contributing to RBP binding disruption and driving the observed signal. 
When applying POLARIS to predict RBP binding in WGS, there were two main questions: 
1. Could we robustly predict binding in a tissue-specific manner, having hopefully regressed out 
the impact of K562 and HepG2 eCLIP tissue in the training process? and 2. Could POLARIS 
implicate specific RBPs or classes of RBPs – as well as their target genes - to developmental 
disorders like congenital heart disease and autism? 
We analyzed the use of POLARIS at the variant level, focusing on mutations belonging to 
the previously implicated enriched RBP subsets and near one of 253 known CHD genes (from 
mouse knockout experiments) for best signal-to-noise. We then ran POLARIS on these variants 
for all 160 available RBPs, for both reference and alternate sequence. Comparison of reference 
and alternate binding scores revealed both multiple loss-of-function (LOF) and gain-of-function 
(GOF) variants, with significant changes to their POLARIS prediction as a result of the single 
nucleotide change (Figure 2.9). The most disruptive variants (furthest from the identity diagonal, 
and with high reference or alternate binding score) have been highlighted in Table 2.1. 
Particularly interesting target genes among this highlighted set’s variants are NOTCH1, GATA4, 
SOS1, ANKRD11, ZEB2, CCDC40, DNM2, and SHOC2, all with multiple significant disruption 
entries. ANKRD11 had the most (3) recurrent RBP binding-disruptive variants with the RBPs 
SRSF9, XRN2, and PCBP2 all disrupted, while we remind that SHOC2 was one of the genes 
already prioritized in our research earlier by the union of transcriptional and post-transcriptional 
investigative approaches described in Chapter 1. Also of special note is that many of the top 
disruptions are mediated by QKI, a constrained RBP responsible for mRNA splicing regulation 
that has recently been implicated as critical in both cardiac myofibrillogenesis [68] and 
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microglial phagocytosis in nerve tissue demyelination function [69, 70]. The top variant that 
stands out with this combined prioritization schema is chr8:11565875 C→A mutation in CHD 
sample 1-10377, which disturbs QKI binding to a well-known CHD gene GATA4 [8, 71, 72]. 
  
Figure 2.10. RBP binding disruption by highlighted CHD case variants. 
This heatmap plot shows the variant-level effects of ref→ alt change. We prioritized candidate variants to 
focus on with two criteria: 1. They belonged to one of the 7 highlighted relevant RBP subsets described in 
Chapter 1, Figure 1.2 and 2. The gene nearest to them was one of 253 known CHD genes (from knockout 
experiments in mice).Variants above the green diagonal and below the blue diagonal are most significant 
gain-of-function (GOF) and loss-of-function (LOF), respectively, for a particular RBP binding change. 

















Table 2.1. RBP binding disruption by highlighted CHD case variants. 
This table outlines the significant |Δ| > 0.1 variant-level effects of ref→ alt allele change, observed in the 
prioritized de novos set described in Figure 2.8 above. LOF, GOF rows have negative, positive ref → alt 
Δ values, respectively. The most interesting target genes and RBPs are bolded for additional emphasis. 
 




POLARIS binding predictions 
ref alt ref → alt Δ 
chr1 94964605 A G 1-12201 ABCD3 K562.PUS1 0.312 0.422 0.110 
chr16 89361696 G A 1-10051 ANKRD11 HepG2.SRSF9 0.486 0.334 -0.152 
chr16 89432708 G A 1-04540 ANKRD11 HepG2.XRN2 0.153 0.044 -0.110 
chr16 89432708 G A 1-04540 ANKRD11 HepG2.PCBP2 0.391 0.282 -0.109 
chr17 78010739 C T 1-07741 CCDC40 HepG2.PPIG 0.390 0.212 -0.179 
chr17 78010739 C T 1-07741 CCDC40 K562.HNRNPK 0.268 0.152 -0.115 
chr16 3778821 G T 1-09585 CREBBP HepG2.SRSF7 0.266 0.122 -0.144 
chr19 10905977 C T 1-02413 DNM2 HepG2.SLTM 0.470 0.291 -0.180 
chr19 10856986 G A 1-01260 DNM2 K562.CPSF6 0.030 0.131 0.101 
chr9 140710039 G A 1-02194 EHMT1 HepG2.EIF3D 0.621 0.743 0.122 
chr4 5586373 G A 1-07210 EVC2 K562.EIF4G2 0.246 0.129 -0.117 
chr16 53800205 G A 1-02267 FTO K562.FXR2 0.535 0.415 -0.120 
chr8 11565875 C A 1-10377 GATA4 K562.QKI 0.365 0.243 -0.122 
chr8 11565875 C A 1-10377 GATA4 K562.AGGF1 0.221 0.114 -0.107 
chrX 133081915 C T 1-05084 GPC3 HepG2.EIF3D 0.273 0.378 0.105 
chr14 31674826 T G 1-04232 HECTD1 HepG2.QKI 0.265 0.457 0.193 
chr2 33340562 G A 1-05911 LTBP1 K562.SMNDC1 0.275 0.153 -0.123 
chr19 4107088 G T 1-01441 MAP2K2 K562.SND1 0.518 0.371 -0.147 
chr17 56283630 G A 1-00969 MKS1 K562.SMNDC1 0.296 0.177 -0.119 
chr17 29559450 T C 1-00825 NF1 K562.RBM15 0.614 0.395 -0.219 
chr9 139428271 C T 1-05365 NOTCH1 HepG2.EIF3D 0.336 0.590 0.254 
chr9 139397035 C T 1-06740 NOTCH1 HepG2.LIN28B 0.054 0.162 0.108 
chr1 5965560 C T 1-04926 NPHP4 HepG2.EIF3D 0.292 0.400 0.108 
chr2 61258520 T C 1-00174 PEX13 HepG2.DKC1 0.310 0.417 0.107 
chr3 12633190 G A 1-03020 RAF1 HepG2.DDX6 0.152 0.342 0.190 
chr3 78899504 T C 1-12201 ROBO1 HepG2.HNRNPM 0.520 0.732 0.212 
chr16 53660644 G A 1-09044 RPGRIP1L K562.FXR2 0.366 0.198 -0.167 
chr16 53660644 G A 1-09044 RPGRIP1L HepG2.SRSF7 0.483 0.378 -0.105 
chr10 79800490 C T 1-10067 RPS24 K562.HNRNPU 0.202 0.012 -0.190 
chr10 112708640 C T 1-12723 SHOC2 K562.QKI 0.629 0.392 -0.238 
chr10 112716294 T C 1-02231 SHOC2 K562.CPSF6 0.028 0.153 0.125 
chr1 2178029 G A 1-07340 SKI K562.EFTUD2 0.082 0.201 0.119 
chr2 39344418 C G 1-02112 SOS1 K562.HNRNPUL1 0.228 0.056 -0.172 
chr2 39339901 C G 1-00976 SOS1 K562.HNRNPM 0.643 0.479 -0.164 
chr3 30655260 G T 1-08326 TGFBR2 HepG2.U2AF2 0.170 0.064 -0.105 
chr3 30655260 G T 1-08326 TGFBR2 HepG2.FKBP4 0.341 0.240 -0.101 
chr16 2113696 T C 1-05153 TSC2 HepG2.FAM120A 0.266 0.454 0.189 
chr7 158664370 C G 1-03972 WDR60 HepG2.SMNDC1 0.200 0.306 0.106 
chr2 145277438 A C 1-06469 ZEB2 K562.HNRNPK 0.421 0.276 -0.145 
chr2 145277438 A C 1-06469 ZEB2 K562.EWSR1 0.398 0.292 -0.106 
chr8 106699249 T C 1-00801 ZFPM2 K562.HNRNPA1 0.266 0.155 -0.111 
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2.2.11 Harnessing POLARIS to predict individual variant pathogenicity 
 
Finally, we wanted to explore whether POLARIS binding predictions could be used to 
actually predict pathogenicity of individual, RBP-disrupting noncoding variants. As proof of 
concept, we developed a classifier to separate labelled pathogenic regulatory variants in HGMD 
[73] from random common variants in gnomAD [74] (Figure 2.10a). The features used were 160 
RBP predictions for the reference sequence, 160 parallel predictions for the alternate sequence, 
and several gene-level features (ExAC pLI, gene expression logTPM values in multiple tissues) 
to help indicate constrained genes. We saw non-random classification even with simple elastic 
net models, and a reasonable separation of HGMD from gnomAD variants when we employed 
gradient boosting with a sufficiently high number of trees (Figure 2.10b,c). Notably, adding 






       
 
Figure 2.11. Gradient Boosting to Learn Pathogenically Relevant POLARIS Alt-Ref Score Pairs 
a) Model architecture of the supervised machine learning classifier to distinguish HGMD (pathogenic) 
mutations from gnomAD (benign) variants, primarily using reference sequence RBP binding predictions 
and possibly disrupted alternate sequence ones. Nearest gene features (expression, haploinsufficiency, 
epigenomic marks) are also included in the model to promote more relevant genes that are likelier to 
result in pathogenic effect if dis-regulated.  
b,c) ROC and Precision-Recall curves comparing separation of HGMD variants from random gnomAD 
for different models. With a sufficient number of gradient boosting trees, and addition of nearest gene 
expressions and pLI features, there is decent recall even at 75%+ precision. 
a)                                                            
b)                                          





In this chapter, I described POLARIS (Prediction Of Localized Affinity for RBPs In 
Sequence), a new deep-learning method that is an integration of a CNN to predict RBP binding 
to the transcribed genome from genomic sequence, nearest gene expressions, and region type 
annotations, with a GradCAM implementation for efficient localization of this signal 
backpropagation to individual sequence positions. We demonstrated that the model is able to 
achieve very strong RBP binding prediction performance (~0.957 median AUC) that 
outperforms traditional sequence-only based prediction models and competing neural networks. 
Indeed, the results of DeepSEA (median AUC = 0.871) and LS-GKM (median AUC = 0.892) 
on our held-out validation set were more comparable to the performance of our basic POLARIS 
model framework, which does not include expression or region annotation data; this suggests 
that the biological mechanisms that drive feature selection in POLARIS are a big part of what 
helps our model outperform existing methods. By incorporating these additional factors (gene 
expression, region type) into its base feature set, POLARIS is able to reach optimal validation 
set performance with fewer convolutional filters, and is consequently easier to parse and 
understand. Thus, despite utilizing neural networks, POLARIS is both interpretable and 
biologically grounded, important qualities to be able to verify results, investigate the genetic 
underpinnings driving model predictions, and make educated application of the model in 
downstream analyses.  
Regarding model architecture, POLARIS model layers have clear roles: upper convolutional 
layers handle the bulk of RBP motif learning, later convolutional layers are responsible for 
incorporating more distal effects like global RNA secondary structure, and the intermediate 
dropout and max pooling layers help select representative data, minimize risk of overfitting, and 
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enhance learning efficiency. Keeping POLARIS extremely condensed was not a top priority, 
since even the full 1kb models do not take up much storage space or runtime on modern 
machines or clusters: thus, we decided to learn a large number of informative filters (100) for 
each RBP individually, rather than dilute model power with individual filters for each RBP 
within one structure. At the same time, we use various regularization techniques throughout the 
model (L2 regularization in convolutional layers, followed by Max Pooling and Dropout), which 
combined with our relatively simple architecture help reduce overfitting risk despite a large 
number of total trainable parameters. Our experiments with a recurrent neural network (RNN) 
hybrid model did not provide any notable performance gain (median AUC only 0.933). This 
implies that our final CNN-based POLARIS model is sufficient in capturing hidden sequential 
information that is actually useful for in vivo binding prediction. 
We took several important steps to optimize training and guide the model towards learning 
real biological and genetic properties. For instance, without the step of accounting for GC 
content in the randomly sampled negative training sequences, the prediction model could 
inadvertently learn confounding patterns in the data that are not directly relevant to RBP 
binding. We also minimized overfitting risk within our robust training and evaluation 
procedures, although we caution that all of the original RBP binding data was generated 
exclusively with eCLIP experiments from ENCODE – thus, it is not possible to rule out that 
some aspect of POLARIS models artifacts from eCLIP experimental protocol. We contend that 
this is unlikely to be significant, and future testing on alternative data sources will confirm the 
full generalizability of our model to arbitrary sources of sequence binding data. Finally, our 
reported POLARIS AUCs were taken from validation set performance, which was entirely 
isolated during model training and selection. Performance remained high (median AUC ~ 
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0.942) even when using cross-cell evaluation, despite eCLIP overlap being relatively low and 
therefore making this a challenging test. Altogether, these results indicate that our model 
successfully learned sequence motifs and general in vivo binding affinity patterns for each 
given RBP, rather than over-fitted patterns unique to a certain tissue or region context. 
In accordance with expectations, we also saw that as the sample size for an RBP increases, 
so too does its model performance: this is because neural networks require sufficiently large 
training sets to be able to accurately learn patterns within the dataset, so with more data, the 
model has more information to learn from to outperform competing models at prediction of in 
vivo RBP binding. To address the issue of variable eCLIP data quality and sample sizes, we 
recommend fine-tuning binding threshold cutoffs for all RBPs to have consistent FDR that suits 
the experimental context; our approach is described in Chapter 3 Methods (section 3.4.2). In 
this way, use-cases involving simultaneous integration of multiple RBPs will have more stable 
and consistent behavior across all analyzed RBPs. POLARIS model performance being not 
only high but also robust across RBPs and cell line allows for extrapolation and utility in 
tissues other than those necessarily present in the training set: this directly counters the critical 
hurdle of sparse data, which inevitably presents itself when trying to build such models with the 
goal of generalizability. 
We show that our performance gain over competing models is plausible in two key ways: 1. 
evidence that the performance gain over simpler competing models such as PWMs and SVMs 
can be attributed to implicit learning of real biological factors such as RNA secondary 
structure, and 2. Direct extraction and visualization of informative RBP binding motifs, using 
our implementation of gradient-weighted class activation mapping. Although POLARIS saw a 
performance boost with RNAplfold when limited to a narrow 10bp window size, inclusion of 
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these structure profiles did not boost 1kb POLARIS model performance when given 
sufficiently large input sequence length. As suggested by Koo, et al., this indicates that the 
original model is already able to implicitly capture this information within later convolutional 
filters. While we caution that the dynamic nature of secondary structure and inaccuracy of 
prediction can confound the analysis, this apparent secondary structure learning from distal 
sequence represents a very important advantage when modeling in vivo RBP binding instead of 
merely motif match/mismatch. Another helpful factor could be our more careful curation of 
representative training data, including upstream fine-tuning of eCLIP peaks with CLIP Tool Kit 
(to improve resolution of protein-RNA interactions by determination of exact crosslink sites 
and connection of peak valleys) and RBP-specific training with custom GC-balanced negative 
sets. These steps help the model focus on learning only representative motifs and relevant distal 
features for binding prediction, rather than noise or biases in the data. It is common in the field 
to use random eCLIP sites of other RBPs as negatives for a given RBP, in order to control for 
eCLIP experimental protocol and regional preferences. However, we believe that our 
transcribed, GC-balanced negative regions could actually account better for the most prominent 
of these factors for each individually trained RBP, while simultaneously enabling our model to 
minimize any biases against RBP complexes, the primary way in which RBPs physically act 
upon transcripts in reality. Additional validations on alternate sources of RBP sequence binding 
data, such as older cross-linking immunoprecipitation (CLIP-seq) data, will be required to 
verify this intuition.  
Finally, POLARIS’ GradCAM module provides a method to interpret the prediction in a way 
similar to conventional binding motifs without the limitation of linearity. This ability to 
efficiently backpropogate binding signal to subsections of the input sequence driving the 
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prediction (at single base pair resolution) is a novel addition to the field of genomic binding 
modeling with CNNs. It is useful both for localizing overall RBP binding predictions and for 
quickly extracting biologically-grounded RBP binding motifs, equally canonical and novel ones. 
Our weighted hierarchical clustering algorithm can break down GradCAM heatmaps into 
binding sites and valleys, with flexible motif length and number of motifs per window that better 
mirror the variability inherent in the diverse binding patterns of different RBPs. This clustering 
method has difficulty in cases of lower POLARIS binding score, which could perhaps be 
addressed with hyperparameter tweaks and additional sophistication on distance matrix D to 
rapidly decay pairwise similarity in beyond certain reasonable motif lengths. Hierarchical tree 
cut height h = 1 was observed to work well in practice, but could be further optimized based on 
concrete experiments on RBP motif extraction. Overall, with its focus on localized prediction, 
POLARIS is especially well suited for in vivo binding motif interpretability and downstream 
variant effect prediction. In particular, we hope that our work on POLARIS will lead to 
development of new, more accurate noncoding variant pathogenicity models that can leverage 
position-specific binding predictions. 
POLARIS is a useful tool both at gene-level and at variant-level, which independently 
considers and compares binding on reference and alternate sequences. In our previous analysis 
(Richter et al 2020), we had used tissue-specific H3K36me3 histone mark as a proxy for 
transcribed gene regions; combining it with K562 and HepG2 RBP eCLIP data gave us an 
estimate of active RBP sites in tissues relevant to CHD (fetal heart, embryonic stem cells). 
However, with its variable gene expression vector input, POLARIS offers a much more direct 
solution that is also able to find new sites rather than only limit to subset from existing tissues. 
Analysis of the CHD Whole Genome Sequencing data with POLARIS yielded several key 
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variants, RBPs, and target genes that we could previously only implicate as enriched subsets in 
combinatorial burden analysis. Most interesting among the known or high-confidence candidate 
risk CHD genes (curated by Jin, et al., 2017 [16]) were NOTCH1, GATA4, SOS1, ANKRD11, 
ZEB2, CCDC40, DNM2, and SHOC2, all with multiple significant disruption entries, and the 
RBP QKI, which regulates mRNA splicing regulation for many of the most disturbed genes in 
our results. The top variant that stands out with this combined prioritization schema is 
chr8:11565875 C→A mutation in CHD sample 1-10377, which disturbs QKI binding to the 
extremely well-known CHD gene GATA4. One can envision a targeted experimental testing 
framework to individually knock out these RBPs in a model organism (such as mouse) in both 
wild-type and variant contexts, and biologically validate that there is greater damaging effect in 
the former than when a binding site is already predicted disturbed by POLARIS via an indel or 
point mutation. This would indicate that this proposed gene regulatory mechanism was indeed a 
very likely critical component for congenital heart disease, and add another convincing layer of 
validation to our model. 
Regarding our HGMD vs. gnomAD super-model proof-of-concept, the big performance 
boost over the baseline expression-only and pLI-only models when integrating POLARIS 
binding scores indicate that our model predictions add novel information, are indeed sensitive 
to RBP disruptions, and can help prioritize pathogenic variants in studies. In general, the way 
POLARIS compresses relevant types of genomic sequence features is powerful, and we hope 
that this multi-faceted new model will prove useful in helping uncover deeper insights into 






2.4 Materials and Methods 
 
2.4.1 Data processing for RBP binding model 
 
We obtained eCLIP (enhanced crosslinking and immunoprecipitation) RBP binding data 
from ENCODE [22] , from experiments originally done by Gene Yeo’s lab at UCSD. eCLIP 
data is stored as rows of peaks, specifying chromosome, start, and end position of each peak 
together with an associated p-value. Of course, because they are derived from imperfect physical 
experiments, there is some noise in the data. Chaolin Zhang’s lab has made strides in sharpening 
the binding signal from eCLIP datasets (“CLIP Tool Kit”, Shah 2016 [35]), and it is this latest 
processed data that we use in our analyses. In total, we acquired binding data for 112 unique 
RBPs from the adrenal gland, HepG2, and K562 cell lines, for a total of 160 separate RBP 
eCLIP peak files. Our final positive dataset for the RBP binding model was generated from this 
eCLIP data by first removing singular peaks that are not within 500bp of any other peak for a 
given RBP, and also excluding peaks with p-values > .01 to minimize the presence of noisy data.  
These peaks were further processed with CLIP Tool Kit (CTK) [35] into narrower, higher 
confidence sets of in vivo binding sites for each RBP; these positive training data regions 
indicate true RBP binding either within or close to them. Finally, the regions were padded 
(equally) on both sides to 1kb total sequence length each in order to ensure that the binding 
motifs were contained within the input contexts, and to be able to learn binding effects from 
more distal sequence elements. 
The negative dataset was generated by randomly sampling transcribed sequences (pre-
mRNA transcripts) along the hg19 refGene genome from UCSC. The sequences are also 
constrained to the full peak ranges of their corresponding cell line, and only include at most 
500bp of non-transcribed regions. Since the positive sequences were padded up to 1kb, the 
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negative sequences were allowed to overlap with positive sequences, by at most 200bp. These 
random sequences were also evenly distributed between the positive and negative strands, which 
matches the strand distribution of the positive dataset. 
Each one of these positive and negative sequences was then one-hot encoded and combined 
into a 3D tensor, thereby creating a vectorized representation of the sequence strings. Since the 
sequences have variable length, empty space was added to the end of shorter sequences as 
padding in order to ensure consistent dimensionality throughout the tensor. 
 
2.4.2 RBP binding model architecture details 
 
In POLARIS’ CNN, the convolution layers compute output by one-dimensional convolution 
operation with a specified kernel size and number of filters. Then, the pooling layers compute 
the maximum value in a specified window of spatially adjacent convolution layer outputs for 
each kernel. The fully connected dense layers on top of the second convolution receives input 
from all of the outputs from the previous layer, thereby integrating information from the full 
sequence length. The dense layers perform a rectified linear (ReLU) activation to the hidden 
unit cells: 
 
Finally, the sigmoid output layer makes a prediction of whether or not the RBP will bind to 
a given sequence, and scales the prediction to the 0-1 range by the sigmoid function: 
 
In order to prevent overfitting, a proportion of outputs were randomly set to zero at some of 
the layers. A dropout proportion of 15% was added after layers 2, 4, and 7. Both of the 
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convolution layers also had an L2 regularization term of .01, which again, was used to minimize 
overfitting and add some robustness to the training process. Finally, this model uses a stochastic 
gradient descent optimizer and a binary cross-entropy objective loss function: 
 
This model was trained with a batch size of 16 and 10 epochs, which was empirically 
observed to lead to a plateau in performance. Specific architecture and hyperparameters are 
outlined on our GitHub page (see Appendix). 
Both of the RNN models use a binary cross entropy loss function and an RMSprop 
optimizer. They were trained with a batch size of 100 and ran for 10 epochs. Specific 
architecture and hyperparameters are again outlined on our GitHub page (see Appendix). 
In the current version of POLARIS, individual RBP models do not share layer parameters 
amongst themselves; we made this design decision to concentrate power to detect each 
individual RBP, rather than force the filters to multi-task (with less controlled negative set data, 
since GC balancing is unique to each RBP). However, after individual training these models can 
trivially be joined together with a shared input layer, to have a more condensed full model that 
simultaneously predicts binding for all RBPs at once. 
All neural network models mentioned above were built using the Python keras package with 
a GPU-accelerated Tensorflow (v2.2) backend, and trained using a machine with one Nvidia 
GTX1080 graphics card (2560 CUDA cores) and 8 GB RAM. With these specifications, the full 





2.4.3 Annotations and gene sets 
Variants were generally annotated using ANNOVAR (v2017-07-17). Region type 
annotation was done with the annotatr R package, from the Bioconductor suite. 
 
2.4.4 Gradient-weighted Class Activation Mapping (GradCAM) implementation 
 
We implemented the Gradient-weighted Class Activation Mapping (GradCAM) algorithm 
design described in Selvaraju et al., 2017 [67], with the simple modification that instead of 
projecting onto a u x v dimensional image, we find the activation map onto a one-dimensional 
vector of length L base pairs for the case of our RBP binding model (which only performs a one-
dimensional sequence convolution, rather than 2D “image” convolution). In order to obtain the 
class-discriminative localization map 𝑀𝐺𝑟𝑎𝑑𝐶𝐴𝑀
𝑐 𝜖 𝑅𝐿 of length L base pairs for any RBP class c, 
we first compute the gradients via backpropagation of class c’s score 𝑦𝑐, with respect to feature 
map / filter activations 𝐴𝑘, i.e. 
∂𝑦𝑐
∂𝐴𝑘
⁄ . These gradients flowing back are global-average-
pooled over the length dimension (indexed by l) to obtain the neuron importance weights 𝛼𝑘
𝑐  :  
𝛼𝑘









Equation 2.2. Averaging class-specific filter activations to find GradCAM neuron importance 
During computation of 𝛼𝑘
𝑐  while backpropagating gradients with respect to activations, the 
exact computation amounts to successive matrix products of the weight matrices and the gradient 
with respect to activation functions till the final convolution layer that the gradients are being 
propagated to. Hence, this weight 𝛼𝑘
𝑐  represents a partial linearization of the deep network 




We perform a weighted combination of forward activation maps, and follow it by a ReLU to 
obtain  
𝑀𝐺𝑟𝑎𝑑𝐶𝐴𝑀




Equation 2.3. Calculation of GradCAM localization by weighting forward activation maps 
 
Notice that this results in a coarse heatmap of the same dimensionality as the convolutional 
filters, but is easily stretched back up to the original input size for projection (151 positions, in 
the case of our RBP binding models). A ReLU is applied to the linear combination of maps 
because we are interested in the features that have a positive influence on the class of interest; as 
Selvaraju, et al. note, negative “pixels” or positions are likely to belong to other categories and 
GradCAM localization performance is decreased without this ReLU operation. In total, for each 
sequence we can end up with 160 L-length GradCAM heatmaps, one for every RBP class c, that 
highlight the most relevant regions of the input for placement in each respective class.
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Chapter 3: SUPRNOVA, a graphical neural network to predict 
genetic impact of rare noncoding variants 
 
We aim to predict the genetic impact of rare noncoding variants that can be applied to genetic 
analysis of human conditions. We developed SUPRNOVA, a super-model integrating POLARIS 
within a graphical neural network to learn selection effects from population genomes data and 
RBP binding strength differences between reference and alternate sequence. The main idea of the 
SUPRNOVA model is to combine information from RBP binding affinity changes (“cause”; 
molecular and cellular mechanisms) and allele frequency (selection effect; population 
mechanisms) to improve estimation of genetic impact of noncoding variants at organism level. 
While POLARIS models RBP disruption effects at molecular level, SUPRNOVA extends this to 
the population level via genetic selection and resulting allele frequency constraint: by doing so, 
we can jointly estimate functional damagingness and selection coefficient while learning 
upstream RBP interaction patterns. We present SUPRNOVA as a natural, biologically-grounded 
framework to pool genetic information across many different sites. In addition to predicting gene 
regulation damagingness and selection coefficients of individual variants, we hope the method 
will also prove useful in elucidating biological links between noncoding mutations, disruption of 
RBP complexes, dysregulation of post-transcriptional gene regulatory processes, and ultimately 
effect on fitness via selection. In this section, I describe SUPRNOVA model design and 

















Naively, when trying to predict noncoding variant damagingness through disruption of 
transcription factor or RBP binding, we are interested in the Δ between wild-type and mutant 
binding predictions. However, the binding score cutoffs can differ across RBPs and contexts: for 
example, it is very unclear how a 0.8 → 0.6 (ref→ alt) change compares to 0.95 → 0.75 “full” 
disruption or an even trickier case of 0.55 → 0.35, despite all three scenarios losing 0.2 
magnitude of binding score. A still greater question is which RBPs are critical enough to trigger 
significant disruption of the target gene when their binding site is disturbed by mutation: not all 
RBPs are equally important, and thus not all will lead to an equal selection consequence. This is 
complicated further by the fact that RBPs tend to work together in protein complexes, meaning 
that there are many implicit interaction terms to consider when trying to predict variant effect. 
To answer all of these questions, we require a larger (super) model that can use the knowledge 
from individual binding (sub) model(s) to learn relevant binding disruptions. 
In our presentation of POLARIS in Chapter 2, we demonstrated its utility in such a super-
model framework. Our proof-of-concept supermodel seeks to classify transcribed noncoding 
variants as originating from HGMD “labeled pathogenic” database, vs. originating from random 
(benign) gnomAD sampling. The gradient boosting method was able to separate HGMD from 
gnomAD with decent success (AUC ~ 0.8), using only reference and alternate binding scores 
(for 160 RBPs) and two types of gene-level relevance properties: tissue expressions and gene 
constraint. However, this approach has several notable limitations. Most critically, labelled 
pathogenic noncoding variant data sets are very limited and HGMD is not an exception, having 
only ~3000 regulatory noncoding entries (of which a minority play a role in post-transcriptional 
regulation via RBPs). These data sets are also notoriously noisy, with many “pathogenic 
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noncoding mutations” mislabeled or summarized from debatable evidence. On the methods side, 
while gradient boosting is a strong out-of-box classifier for learning interacting features such as 
relevant ref→ alt binding prediction differences, it is limited in capturing more sophisticated 
complex graphical models. Below we discuss the improvements that can be made regarding both 
data and methodology, and our new method development to model and predict noncoding 
variant pathogenicity in a more robust, illuminative way. 
We begin by noting that natural selection will act to slowly remove harmful variants from 
populations of organisms, with allele frequency depletion at a site strongly suggestive of 
pathogenicity. Established models in population genetics show that allele frequencies (AFs) is 
correlated with selection coefficient [75-77]; indeed, with infinite sample size positional AF 
would be sufficient by itself to perfectly identify harmful variants. While still limited, population 
genetics databases like gnomAD can be utilized to label AF: instead of HGMD’s <3000 
noncoding regulatory mutations, gnomAD 3.0 [74, 78] contains numerous orders of magnitude 
more variants from 71,702 reference Whole Genomes. Selection coefficient shet or s ϵ [0,1] is the 
relative fitness of the heterozygote (ie: de novo mutated) compared to wild type. Together with 
background mutation rate µ, s determines the expected allele frequency via Equation 3.1 [75]:             
 
 
Equation 3.1. Relationship of expected allele freq. to background mutation rate and selection coefficient 
 
Here, c and the constraint limit are some constants that need to be estimated from data in 
the case that selection is extremely weak at a site and s ~ 0. The allele frequency equation has 
two parts because 𝐸(𝐴𝐹) = µ / s is only true in the case of strong selection; otherwise, AF is 
largely determined by random genetic drift. Note that effective population Ne can also be 
E(AF) =  {
µ ∗ 𝑁𝑒 ∗ 𝑐,  𝑖𝑓 𝑠 <  constraint limit




variable here dependent on population history: for instance, Ne is relatively small for common 
variants that passed through population bottlenecks such as humanity’s migration from Africa, 
but for rare variants, which were often generated recently, Ne is large (potentially over 20,000). 
We show an example calculation below to offer an intuition of the problems that must be 
tackled: 
Assume background mutation rate µ is ~10-7 in CpG sites, ~10-8 otherwise. 
Selection coef. s can be ~ 0.01 to 0.02 for a noncoding variant, via autism. 
Then µ / s is ~5 * 10-7 to 10-5, and consequently ~2 million genomes are needed                   
for an expected allele count E(λ) ≥ 1.  
As described earlier, even the latest gnomAD 3.0 only contains 71,702 genomes, which is 
still well short of 2 million. To overcome this low sample size / high noisiness problem, we 
design a neural network according to the following three key principles: 1. Harness allele 
frequency via the equation above to tie trainable predicted AF to selection coef. s as a marker of 
pathogenicity (genetic effect). 2. Calculate an informative Loss and gradient even in the case of 
the extremely common AF = 0 “Zeroton” sites. 3. Backpropogate the gradient through the 
network to learn useful genetic patterns (genetic cause). For this purpose, we introduce our 
method SUPRNOVA (Selection Upshot Prediction of Rare NOncoding VAriants), a graphical 
neural network that combines genetic cause and effect to allowing simultaneous learning of post-
transcriptional gene regulation damagingness, variant selection coefficient, and the RBP binding 
disruptions driving the observed change in genetic fitness. The core concept is illustrated in the 
probabilistic graphical model below, for the generalized case of moving from relevant variant-
level representations to molecular effect and consequently to variant depletion in population  





Figure 3.1. Probabilistic graphical model to jointly estimate the impact of genetic variants at the 
molecular and population levels.  
𝑋: representation of a genetic variant in its regulatory context; 𝐷: molecular effect; 𝑠: selection 
coefficient, 𝑁: number of population genomes; 𝑢: mutation rate. 𝑝Φ(𝐷|𝑋) is a neural network; 𝑝Ψ(𝑠|𝐷) is a 
concatenated logistic function; 𝑝(N,µ)(𝑚|𝑠) is governed by a negative binomial distribution. 
 
In effect, SUPRNOVA uses POLARIS’ RBP binding predictions to “pool” together variants 
with similar molecular impact, effectively expanding sample size to estimate allele frequency. 
The model compares observed and predicted AF for many sites, considering background, and 
backpropagates the gradient back up to the RBP binding activations, allowing the neural network 
to learn disruptions with selection upshot / consequence. The current version considers all 
variant possibilities at a site, predicting three different, alternate allele-specific selection 
coefficients for the central position in the input genomic region. 
SUPRNOVA’s task is to essentially learn a feature representation of potential binding 
disruptions for each RBP, for each alternate allele change, and to compress this representation 
down to a latent form that is useful and generalizable for “prediction” of allele count in 
population genomes data. In other words, the model should learn a mapping from predicted RBP 
binding changes to a representation of aggregate gene damagingness, which combined with 
gene-level constraint properties should allow forecasting of variant selection coefficient s. This 
raises the important issue of how to treat the complicated initial 4-D tensor (dimensions N 
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sequences by L positions by R RBPs by 4 allele variants) and process it in a way that quickly 
simplifies the features and makes it tenable for a neural network to notice patterns in. For 
instance, any convolution operation across 160 RBPs will capture interaction terms and be able 
to weigh RBPs in theory, but convolution filters with a dimension of 160 are extremely 
cumbersome in practice, overly sparse, and difficult to train in a generalizable way. We propose 
in the next section to first convolve RBPs together into likely complexes, resulting in much 
smaller, simpler filters. This is simultaneously a more accurate modeling of the biological 
processes involved, since RBPs seldom work alone and are much more often found interacting 




3.2.1 RBP clustering to simplify SUPRNOVA convolution structure 
 
We order RBPs using clustering by eCLIP site overlap frequencies. Overlap between eCLIP 
datasets A and B is determined by the number of overlaps divided by the smaller eCLIP count of 
the two, as in Van Nostrand, et al., 2020 [21]. We performed hierarchical clustering (UPGMA) 
on the resulting pairwise distance matrix, which estimates a reasonable RBP ordering and 
suggests potential complexes (Figure 3.2). We are thus able to use much smaller (ie: kernel size 
2-4) convolutional filters in the first CNN layer to directly capture specific, interpretable 
complexes, and only then model effect on gene regulation damagingness as a function of RBP 




                
Figure 3.2. Hierarchical clustering on the eCLIP overlap matrix 
We use hclust to order the 160 RBPs for convolution to potential RBP complexes, based on overlap of 
their eCLIP data. Overlap between eCLIP datasets A and B is determined by the number of overlaps 
divided by the smaller eCLIP count of the two, as in Van Nostrand et al., 2020. Panel a) shows the 
resulting RBP similarity matrix, while b) shows the corresponding hierarchical cluster dendrogram 
(UPGMA). Optimal ordering for SUPRNOVA RBP complex convolutions is lifted from this result.  
 
3.2.2 SUPRNOVA model architecture and Loss function 
 
The primary input to SUPRNOVA (Figure 3.3) is a list of genomic positions, which are 
padded equally on both sides and converted to four genomic region tensors: these represent all 
variant combinations of the central position, one of which is the reference and the remainder of 
which are alternate alleles. Together with a gene expression and a region annotation vector, these 
tensors are fed into the nested “sub-model” POLARIS and output four binding predictions per 
RBP, with all of their respective GradCAM localization heatmaps. A simple multiplication layer 
weighs the GradCAMs by each one’s overall (regional) RBP binding strength, resulting in a 4-D 
tensor with dimensions N sequences by L = 1kb positions by R = 160 RBPs by 4 allele variants. 
Because RBPs can have different optimal cutoffs for confident binding, we use a POLARIS 
tuning function (described in Methods 3.4.2) to find 160 cutoffs resulting in 5% synthetic FDR 
for each RBP. The next SUPRNOVA layer then uses these cutoffs as fixed midpoints for non-
a)                                                             b)                                         
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trainable sigmoid activations that converts each RBP’s scores closer to a (0,1) output. This step 
acts as a sort of thresholding layer to simplify the data and enable cleaner interpretation of RBP 
disruption by the model. We refer to the tensor at this stage as activated RBP bindings. 
The next stage of SUPRNOVA is to convert these RBP bindings to ref → alt deltas: 
subtracting all four alleles from reference yields a (-1,1) binding Δ layer, ~0 when the POLARIS 
score does not cross the learned thresholds, ~1 for strong loss-of-function (LOF), and ~ -1 for 
strong gain-of-function (GOF), calculated per allele, per input sequence. Because of the sigmoid 
activation step in the previous layer, binding deltas are pushed to the edges of (-1,1), again 
aiding in cleaner interpretation of RBP disruption by the model. After generating Δs, we 
compress the data across RBPs by convolving together complex members using the suggested 
clustering order calculated in 3.2.2, and activate with a tanh to emit (-1,1) with sign direction 
representing LOF or GOF at the RBP complex stage. A weighting layer aggregates a (trainable) 
weighted combination of complex disruptions, and this is combined (using a Dense layer) with a 
nearest gene expressions and an epigenomic marks tensor. After some transformations and 
another tanh activation, we get total gene regulation damagingness d ϵ (-1,1), still per allele, per 
sequence. Finally, d is activated with a custom Logistic parameterized by max = shet gene 




Figure 3.3. SUPRNOVA model architecture.  
The current version of SUPRNOVA uses F=10 RBP complex pattern filters of r = 2 RBPs width for both 
convolution layers in the RBP complex disruption layer. 
 
A temporary final output layer (removed after training) is emitted after combining s with 
background mutation rate µ, and it is here that SUPRNOVA compares the estimated allele count 
quantities to the labeled training data ACs. A gradient is determined based on calculated 
likelihood of the observations given background and predicted selection, as well as factoring in 
the distribution of d. Specifically, the SUPRNOVA Loss function consists of two parts: 1. 
Negative Binomial (NB) Loss on s, and 2. Kullback–Leibler (KL) divergence regularization loss 
on d. The first of these, based on the important, recent correspondence between Charlesworth, et 
al. and Cassa, et al., finds probabilities that the observed gnomAD allele frequencies are from 
Negative Binomial distribution parametrized by “# failures” r = 4Neµ and “trial success 
probability”  𝑝 =
1
4𝑁𝑒𝑠+1
 [79-82]. This directs SUPRNOVA to update its model weights such that 
the predicted selection coefficients of future variants are correct, given their observed allele 
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frequency and background mutation rate; in other words, the gradient pushes towards correct 
reconstruction of the allele frequency Equation 3.1 for truly constrained sites.  
On the other hand, the KL loss term KL(q(d)|p(d)) helps normalize the distribution of d 
closer to the expectation of ~Normal. The combined Loss function with pressure on an important 
variable’s distribution follows the procedure of Variational Inference [83], a standard method 
used in other graphical deep learning methods such as Variational Autoencoders [84]. Indeed, 
the core concept is almost wholly lifted over, with the primary difference being that the two 
components of the Loss act on different model variables (s and d, respectively) rather than on the 
same one. We use prior p(d) ~ Normal(0, sd=1/3) to fit three standard deviations into the desired 
domain of (-1,1); q(d) is the approximate posterior distribution of d, calculated at each epoch. 
Although d is tissue-specific in reality, and could be calculated as such with the tissue-specific 
nearest gene expressions and an epigenomic marks tensor inputs, we compress these tissues 
down with a Dense and simplify our representation of gene regulation damagingness to the 
aggregate case right away. The main advantage of this immediate simplification is to avoid 
needing to know tissue covariances when calculating the Normality of d, and in any case it does 
not affect the final prediction of selection, which relates to overall fitness decrease and is not 
tissue specific. 
During training, SUPRNOVA seeks to simultaneously minimize both the negative sum of the 
relevant log likelihood for s and the KL loss term for d; through backpropagation of this 






3.2.3 Training convergence and resulting layer variable distributions 
 
SUPRNOVA converges during training after approximately 150-200 epochs (Figure 3.4). 
It produces the following distributions for each important layer variable (Figure 3.5): Figure 3.5 
panels a) through c) show densities of individual RBP activations (whether in ref or alt), ref-alt 
activated binding change, and RBP complex disruption, respectively. These latter two store 
directional vectors, with positive values indicating loss-of-function (LOF) and negative values 
indicating gain-of-function (GOF). Panel d) shows gene regulatory damagingness; since this 
version of the network can only directly learn from gene-level LOF with gene shet (panel e), we 
currently make the simplifying assumption that gene-level GOF will have similar levels of 
selective pressure as gene knockout (despite this not necessarily being the case for all genes). 
Because of this, absolute value is taken at the damagingness stage to collapse the directionality 
(panel d). Finally, gene damagingness d is passed through a trainable Logistic function 
parameterized by gene shet as the upper bound, to produce SUPRNOVA’s output prediction of 
variant selection coefficient s (panel e); this variable has a similar domain as background 
mutation rate divided by allele frequency, which we expect from formula, and a very modest 
number of variants with severe selection s > 0.1. Thus, it appears reasonable at first glance; we 
demonstrate in the following Results below that s is indeed informative of both variant selection 
and important gene properties, and that SUPRNOVA is genuinely able to learn useful measures 
of damagingness and selection entirely from population allele frequency data and POLARIS’ ref 




Figure 3.4. SUPRNOVA training convergence 
SUPRNOVA training converges after ~150-200 epochs, with similar Loss for training and 
validation splits. A large batch size (1024) was used for a smoother estimate of KL on d. 
 
 
Figure 3.5. SUPRNOVA variable distributions; results from 100k random transcribed variants  
Panels a,b,c) show the distributions of activated RBP bindings, ref → alt binding change, and RBP 
complex disruption, respectively. Panel d) shows the distribution of aggregate gene damagingness d. 
Panel e) shows the distribution of the gene shet input, which sets the max value for the Logistic with which 
d combines to output a prediction for selection coefficient s (panel f). 
a)                                          b)                                         c)  
d)                                          e)                                         f)  
72 
 
3.2.4 Verifying the plausibility of s predictions with site frequency spectra 
 
A site frequency spectrum (SFS; spectra plural) is the distribution of allele counts of some 
collection of variants [77, 85, 86]. Although lack of prevalence in gnomAD for a single variant 
does not carry any confident implications (due to still overly small sample sizes, as we 
discussed), an SFS groups together population data of many variants and thus can be much more 
informative and meaningful. In this way, it is possible to qualitatively say that left-shifted 
distributions with many Singletons (one occurrence in the population data) and Zerotons (no 
occurrences) represent variant sets that are clearly more constrained than those with a high 
frequency of Doubletons, Tripletons, and higher order allele counts.  
In the case of SUPRNOVA or any other forecaster of selection coefficient s, it is important 
to verify that the results correlate well with the expected site frequency spectra; specifically, we 
investigate whether the SFS for the set of predicted constrained variants is indeed left-shifted 
compared to the SFS for the set of predicted non-constrained variants. We first explored this 
question by plotting the SFS of different arbitrary s bins, and checking that the trend appeared 
reasonable (Figure 3.6a). Because allele counts follow a theoretical Power Law distribution [77], 
a common comparison of spectra involves plotting frequency vs. AC in log-scale, wherein they 
should have a linear relationship. Furthermore, the slope is very informative: more deeply 
negative slopes indicate more stringent selection constraint than less negative slopes. We 
observed exactly that result when we ran this experiment across our several s bins (Figure 3.6b), 




Figure 3.6. Site frequency spectrum comparison for different selection coef. s bins  
a) SFS histogram for each bin. b) Power Law lines in log-scale, showing generally steeper negative 
slopes for variant sets with more predicted selection constraint. 
 
To understand this pattern in another way, we also modeled each SFS with a negative 
binomial distribution of best fit (similar to what occurs in SUPRNOVA’s Loss function), and 
compared the parameters of the distributions (Figure 3.7a). In these negative binomials, the mean 
µ = E(AC) is the expected allele count, while size refers to overdispersion relative to a Poisson 
distribution. We found that the 0 < s ≤ 0.001 and 0.1 < s ≤ 1 bins, for instance, have similar 
overdispersion (~0.058) but markedly different E(AC), with variants belonging to the latter bin - 
representing more strongly selected-against mutations - being on average only 0.116 / 0.195 ~ 
59% as prevalent in gnomAD as those in the unconstrained bin. As in the previous analyses, this 
result was limited to CpG sites: non-CpG predicted constrained variants were a full 0.167 / 0.179 
= 93% as prevalent in gnomAD as those in the unconstrained bin, with the dissimilarity in fitted 
NB overdispersion dwarfing this insignificant E(AC) difference (Figure 3.7b). 
a)                                                             b)                                          
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Figure 3.7. Comparison of expected allele count E(AC) = µ for Negative Binomial fits between the 
least and most constrained s bins 
a) CpG sites result, showing 41% lower mean allele count for high s variants compared to low s variants. 
b) Non-CpG sites result, showing only 7% lower mean allele count for high s variants compared to low s 
variants, matching our observations from the other SFS analyses.  
 
3.2.5 Relationship between predicted selection coef. s and regulated gene properties  
 
As well as affecting site frequency spectra, high selection of regulatory noncoding alleles is 
also known to strongly influence the constraint of their respective regulated genes. Like before, 
we made the reasonable (for this purpose) approximation that regulated genes are the nearest 
gene to each respective variant. We tested correlation of SUPRNOVA-predicted s with both shet 
[79] and ExAC pLI of these genes: we remind that the former was used directly as a feature in 
the graphical neural network (as an upper bound for the Logistic function emitting s), while the 
latter is a parallel metric of haploinsufficiency [87]. Predicted s follows a very clear linear 
relationship with shet (Figure 3.8a), a good internal sanity check. Similar to our analysis of s 
buckets for site frequency spectrum, we also analyzed correlation of s vs. ExAC pLI in different 
buckets: the majority of variants even above the low cutoff of 5e-4 have pLI > 0.9  (Figure 3.8b). 
a)                                                            b)                                          
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These results are as expected: even variants that might be highly disruptive of RBP binding 
cannot result in high selection if they regulate non-constrained genes.  
 
  
Figure 3.8. Predicted selection coefficient s vs. regulated gene properties 
a) Heatmap plot showing very clear, upper-bounded linear relationship between predicted variant s and 
gene-level shet constraint (used directly in SUPRNOVA). b) Bar plot showing the proportion of variants 
near constrained genes (defined as ExAC pLI > 0.9, a metric not used in SUPRNOVA) in different s bins, 
similar to the analysis done in Figure 3.09. Sensibly, variants with higher predicted s (even above the very 
modest cutoff of 5e-4) are more likely to be near constrained genes.  
 
3.2.6 Relevant class enrichment with increasing predicted damagingness d 
 
Finally, we investigated SUPRNOVA’s intermediate output of gene damagingness d. 
Unlike s, which combines d with gene-level constraint to summarize overall selection, 
damagingness is only measure of how much a variant disrupts RBP binding, irrespective of gene 
relevance. However, this quantity is still informative and should also have a reasonable 
relationship with biological properties. We investigated the relationship between d and region 
type, annotated as coding sequence (CDS), 5’UTR, 3’UTR, intronic, or one of four SpliceAI-
predicted damaging splice junctions: Acceptor Gain (DS_AG), Acceptor Loss (DS_AL), Donor 
Gain (DS_DG), and Donor Loss (DS_DL) [88]. The recommended “high sensitivity” threshold 
a)                                                             b)                                          
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of 0.2 was used for SpliceAI labels, to maximize the number of such variants included in the 
analysis. We observed a trend of increasing enrichment (vs. intronic variants) of damaging splice 
site variants as the cutoff for d was increased (Figure 3.9). Another interesting trend was the 
decreasing presence of 5’UTR variants as d increases. Most impactful RBP binding for post-
transcriptional processes occurs downstream of genes in the 3’UTR rather than upstream in the 
5’UTR; this is consistent with our interpretation that the model smoothly focusing better on 
















Figure 3.9. Differences in region class distribution of variants with higher predicted gene regulation 
damagingness d (intermediate SUPRNOVA output)  
a) Bar plot of proportions (normalized by total variant count per class and d bucket size) for different d 
bins. The grey bar is an aggregate of all region classes for each bin and with the normalizations described 
is consistently at a height of 1; it has been included in the figure for clarity. b) The full densities of d, 
broken up by each fixed region class type. c) Region class enrichment, particularly via SpliceAI-predicted 










Like with our POLARIS model, model interpretability was a key priority when designing the 
SUPRNOVA neural network. Our model architecture is biologically grounded, with flow from 
RBP binding scores, to individual RBP binding disruptions, to disruptions of RBP binding 
complexes that drive gene regulation damagingness being representative of real genetic 
processes. The KL divergence component Loss on d is a sensible technique for encouraging the 
model to emit more Normally-distributed damagingness at this layer. On the other hand, the 
Negative Binomial (NB) Loss on s, with probabilities that the observed gnomAD allele 
frequencies are from Negative Binomial distribution parametrized by “# failures” r = 4Neµ and 
“trial success probability”  𝑝 =
1
4𝑁𝑒𝑠+1
, also has a clear interpretation. The mean of this NB is the 
same as that of a Poisson distribution with λ =
𝜇
𝑠⁄ ; however, NB variance is overdispersed, 
especially when z = 4𝑁𝑒𝑠 ≪ 1. This overdispersion allows it to better fit the data, since real 
effective population size Ne is inconsistent, being small for common variants (describing a 
population bottleneck, like migration from Africa) but large for rare variants.  
We showed that SUPRNOVA’s predictions were reasonable by comparing several relevant 
gene and variant properties with increasing constraint stringency of s bins and d bins thresholds. 
High predicted selection coefficient appears to match well with more constrained site frequency 
spectrums, and passes sanity check for correlation with nearest gene constraints. On the other 
hand, d is sensibly distributed vs. variant region classes, and high d boosts enrichment of 
variants in SpliceAI-predicted damaging splice sites. The densities of the other intermediate 
layers are certainly very narrowly spiked, but we contend that this is reasonable, since the vast 




A notable caveat in our results is that we could only see the expected site frequency spectrum 
pattern in CpG sites, which have 1-1.5 orders of magnitude higher background mutation rate 
[89-92] due to spontaneously occurring deamination of methylated cytosine to thymine, or 
deamination of thymine to uracil, which is then replaced by cytosine [89, 90, 93-96]. We 
interpret this as indicative of a problem of insufficient power of SUPRNOVA to learn from and 
accurately predict damagingness and selection in non-CpG sites. Specifically, it appears difficult 
for the current neural network to separate variants via RBP disruption when both background 
mutation rate and observed allele count are consistently too low, as is the case with non-CPGs. A 
sample size one order of magnitude larger than gnomAD 3.0’s 71,702 genomes will be required 
to address this limitation and give SUPRNOVA power to discriminate post-transcriptional 
selection effects over the entire genome. We do expect to see such large data sets in the near 
future from ongoing biobank-scale projects such as the UK Biobank Whole Genome Sequencing 
project [97]. 
Although further refinements in data quality and potentially model design will need to be 
made to be able to robustly apply SUPRNOVA to WGS and predict harmful variants with 
perfect confidence, we hope that our work in this project contributes to the difficult question of 
individual variant pathogenicity prediction and related areas of genomics. We contend that our 
general “super-model” framework can be a useful example for how to integrate binding model 
predictions like POLARIS scores (or, for instance, TF binding affinities) within a graphical 
neural network to learn disruption of gene regulatory processes and the resulting selection 
effects. We hope to continue this avenue of research to learn more about genetics and the 
biological links between noncoding mutations, disruption of RBP complexes, dysregulation of 
post-transcriptional gene regulatory processes, and ultimately effect on fitness via selection. 
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3.4 Materials and Methods 
 
3.4.1 Data processing  
 
The population allele frequency data is from gnomAD 3.0, which was built using 71,702 
reference Whole Genomes. We limit random site sampling to transcribed region to make sure to 
focus on post-transcriptional processes where RBPs mostly act. The results shown in this chapter 
are from 100k randomly sampled transcribed sites. 
 
 
3.4.2 Fine-tuning binding threshold cutoffs 
 
For many downstream use-cases involving simultaneous integration and analysis of multiple 
RBPs, it is critical to reduce noise from non-binding sites and to do so in a consistent way across 
all RBPs. To help with this, we include a tuning function with POLARIS that compares 
prediction distributions between positive and negative sets and can determine customized, per-
RBP score thresholds for designating binding (eCLIP vs. control) given fixed arbitrary 
specificity (1 – FPR), sensitivity (TPR), or False Discovery Rate (FDR). For instance, binding 
thresholds for 20% False Discovery Rate are clustered ~0.25, with many RBPs achieve this 
specificity with even lower threshold. On the other hand, a requirement of 5% False Discovery 
Rate pushes most thresholds to ~0.85, more closely matching qualitative investigation of 
“confident binding sites” done with GradCAM visualizations. Two concrete examples of 
threshold fine-tuning are shown below, where the RBPs RBFOX2 (Figure 3.10ab) and YXB3 
(Figure 3.10cd) require very different POLARIS score cutoffs of 0.83 and 0.38, respectively, to 
achieve consistent 5% FDR. Full distribution comparison for various FDR thresholds is shown in 
Figure 3.10e, with more stringent FDR predictably requiring a right-shifted distribution of 
thresholds across the 160 RBPs overall. We note that since our approach uses balanced positive 
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and negative sets due to experimental design (rather than real-world prevalence of positives), the 
False Discovery Rate calculated here is actually a synthetic FDR; however, the goal of consistent 











Figure 3.10. Ensuring consistent tuning of RBP binding thresholds based on differential score 
distributions and fixed synthetic FDR  
a,b) ROC curves for example RBPs RBFOX2 and YBX3, respectively, highlighting the calculated 
estimate points where 5% synthetic False Discovery Rate (FDR) threshold is met by each RBP model. 
RBFOX2 requires a relatively high cutoff of ~0.83 POLARIS binding score, while YXB3 requires a 
much lower binding cutoff of ~0.38 to achieve consistent 5% FDR. c) Binding score distributions for 
positive (red) and negative (blue) validation set regions; RBFOX2 is plotted in the left panel and YXB3 
in the right panel. As expected, positives are much more right-shifted compared to negatives, but there is 
notable overlap where POLARIS has difficulty resolving the correct classification. The precise overlap 
pattern is RBP-specific, consequently explaining the earlier tuning results. d) Overall RBP binding 
cutoff distributions, for all 160 RBPs, for three different FDR thresholds. A requirement of 5% FDR 
pushes most thresholds to ~0.85, more closely matching qualitative investigation of “confident binding 
sites” done with GradCAM visualizations. 
a)                                                            b)                                          
c)                                                                              d)                                          
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3.4.3 Neural network architecture details 
 
The main method is (variant) vSUPRNOVA, which predicts three different, alternate allele-
specific selection coefficients for the central site in the input genomic region. We also 
experimented with (regional) rSUPRNOVA, which predicts an overall measure of selection 
coefficient for every site in the input genomic region, but with alternate alleles aggregated 
together at each site. The combination of these approaches would of course be the gold standard 
approach, but currently it is too combinatorially large and therefore prohibitively 
computationally expensive. Until a combined method can encode such enormous tensors more 
efficiently, we think vSUPRNOVA is the more informative SUPRNOVA version that makes it 
possible to increase batch size and consider more sequences simultaneously during the training 
process (improving, along with gradient smoothness, many things such as accuracy of the KL 
divergence calculation on the density of d). 
In the CNN section of SUPRNOVA (compression of individual RBP binding effects to RBP 
complex effects), the convolution layers compute output by one-dimensional convolution 
operation (across the RBPs dimension) with a specified kernel size of 2 RBPs and 10 filters. 
Then the pooling layers compute the maximum value in a specified window of spatially 
adjacent convolution layer outputs for each kernel. The fully connected dense layers on top of 
the second convolution receives input from all of the outputs from the previous layer, thereby 
integrating information for a maximum RBP complex size of 4 members total. After this, 
rectified linear (ReLU) activation is used (as is standard for CNNs) to focus the network on 




Like in the POLARIS model in Chapter 2, Sigmoid activations were used where noted to 
activate and scale an output to the (0, 1) range: 
 
In the step of converting gene damagingness d to a prediction for selection coef. s, a 
customized Logistic function was used instead to scale output to (0, shet) range, which is just the 
above Sigmoid multiplied by the particular nearest gene shet. In this way, the maximum possible 
prediction for a noncoding variant’s s cannot exceed a gene’s loss-of-function (LOF) shet, 
constraining the output predictions in a sensible way. The role of d is thus to determine where 
the variant should lie on this Logistic function, based on its predicted disturbances of RBP 
binding. 
Unlike POLARIS, we wanted to keep track of LOF and gain-of-function (GOF) effects 
separately in critical stages of the network (note that LOF/GOF determination for RBP binding, 
RBP complex function, and gene regulation damagingness are not necessarily linked and can be 
mismatched, for instance when an RBP works to stall the action of another. To maintain this 
vector directionality, we instead output to (-1, 1) range using the tanh activation function: 
 
In order to prevent overfitting, a proportion of outputs were randomly set to zero at some of 
the layers; for this, Dropout layers were used, always with proportion of 15%.  
The SUPRNOVA model was trained with a large batch size of 1024, in order to improve 
smoothness and enhance accuracy of the KL divergence Loss calculation on the density of d. 
Training was ran for 200 epochs, after which it was empirically observed to lead to a plateau in 
performance (Figure 3.3). 
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The neural network was built using the R keras package with a GPU-accelerated Tensorflow 
(v2.2) backend, and trained using a machine with one Nvidia GTX1080 graphics card (2560 
CUDA cores) and 8 GB RAM. With these specifications, the full SUPRNOVA training process 
takes around 20-30 minutes given 100k training variants. 
 
2.4.4 Annotations and gene sets 
Variants were annotated using ANNOVAR (v2017-07-17). Region type annotation was 





In this dissertation, I presented three closely related projects to computationally interrogate 
the role of post-transcriptional gene expression regulation in genetic risk of developmental 
disorders. A consistent, big challenge inherent in the field is that the effect size, and thus the 
detection power for rare noncoding variants at large is much lower compared to variants 
change protein sequences. To overcome this, my work broadly focused on noncoding genetic 
inference via deep integration of multiple-modal data sets, including enhanced crosslinking 
and immunoprecipitation (eCLIP), whole genome sequencing (WGS), histone modification, 
RNA-seq tissue expression data, and population allele frequency. By leveraging all of these 
different types of genomics data together with advanced statistical and machine learning 
approaches, we showed that it was possible to predict the impact of noncoding variants on the 
post-transcriptional regulation of gene expression mediated by of RNA binding proteins and 
implicate the role of such noncoding variants in human diseases.  
We first applied a combinatorial multi-testing framework to congenital heart disease 
Whole Genome Sequencing data and observed excess burden of noncoding de novo mutations 
in relevant RBP binding sites, strongly supporting a role of such noncoding variants in genetic 
risk of CHD. This finding motivated the rest of my work to develop novel computational 
approaches to predict genetic effect of rare noncoding variants via post-transcriptional 
regulatory disruption. We then developed our convolutional neural network method POLARIS 
to model and understand sequence- and tissue-specific RBP binding affinity, with single-base 
pair localization via an integrated GradCAM module. We demonstrated that POLARIS is 
accurate and interpretable, and presented a comprehensive exploration of its feature encodings 
and applicability to post-transcriptional regulation studies. Finally, we designed a graphical 
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neural network method, SUPRNOVA, to integrate genetic cause and consequence to predict 
functional impact of rare noncoding variants. Our biologically-grounded framework represents 
a unique approach to combine predictions from simpler (sub)models with population genome 
sequence data to simultaneously learn gene damagingness and selection effect. It is also 
extendable to different types of causal input data, such as transcription factor binding 
predictions, and we hope that it proves useful in elucidating the biological links between 
noncoding variants, disruption of different kinds of gene regulatory machinery, and ultimately 
effect on fitness via selection. In summary, we developed new machine learning methods to 
analyze multimodal human genomics data, uncover insights into the workings of noncoding 
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